US20160184436A1 - Transdermal delivery patch - Google Patents
Transdermal delivery patch Download PDFInfo
- Publication number
- US20160184436A1 US20160184436A1 US15/065,510 US201615065510A US2016184436A1 US 20160184436 A1 US20160184436 A1 US 20160184436A1 US 201615065510 A US201615065510 A US 201615065510A US 2016184436 A1 US2016184436 A1 US 2016184436A1
- Authority
- US
- United States
- Prior art keywords
- matrix layer
- range
- tocopheryl
- phosphate
- transdermal delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C2CCC(C)(CCcc(C)C[H])OC2=C([3*])C([2*])=C1O Chemical compound [1*]C1=C2CCC(C)(CCcc(C)C[H])OC2=C([3*])C([2*])=C1O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J7/00—Adhesives in the form of films or foils
- C09J7/20—Adhesives in the form of films or foils characterised by their carriers
- C09J7/22—Plastics; Metallised plastics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D133/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Coating compositions based on derivatives of such polymers
- C09D133/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D139/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Coating compositions based on derivatives of such polymers
- C09D139/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C09D139/06—Homopolymers or copolymers of N-vinyl-pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
- C08K5/0058—Biocides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/49—Phosphorus-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J2301/00—Additional features of adhesives in the form of films or foils
- C09J2301/40—Additional features of adhesives in the form of films or foils characterized by the presence of essential components
- C09J2301/41—Additional features of adhesives in the form of films or foils characterized by the presence of essential components additives as essential feature of the carrier layer
Definitions
- the present invention relates to a composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, and a transdermal delivery patch comprising the composition, or matrix layer.
- Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans and animals.
- Drug delivery technologies have been developed to improve bioavailability, safety, duration, onset or release, of the pharmaceutical compound.
- the present invention relates to a composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, and a transdermal delivery patch comprising the composition, or matrix layer.
- a first aspect of the present invention provides a matrix layer for use in a transdermal delivery patch for administration of a biologically active compound, the matrix layer comprising a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound and a polymer carrier wherein the polymer carrier is present in an amount within the range of about 30% w/w to about 95% w/w.
- the present invention also provides use of the composition, or matrix layer, in a transdermal delivery patch for administration of a biologically active compound.
- a second aspect of the present invention provides a transdermal delivery patch for administration of a biologically active compound comprising the composition, or matrix layer.
- the composition, or matrix layer may be a solid or semi-solid layer.
- the transdermal delivery patch may comprise further layers.
- a third aspect of the present invention provides a method for preparing a transdermal delivery patch for administration of a biologically active compound comprising the steps of:
- the present invention relates to a composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.
- the composition, or matrix layer may form part of a transdermal delivery matrix patch. It has been surprisingly found that a transdermal delivery patch comprising this composition, or matrix layer, can effectively administer biologically active compounds.
- composition, or matrix layer comprises a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound.
- Vitamin E exists in eight different forms, namely four tocopherols and four tocotrienols. All feature a chroman ring, with a hydroxyl group that can donate a hydrogen atom to reduce free radicals and a hydrophobic side chain which allows for penetration into biological membranes. Such derivatives of vitamin E may be classified as “hydroxy chromans”. Both tocopherols and tocotrienols occur in alpha, beta, gamma and delta forms, determined by the number and location of methyl groups on the chroman ring. The tocotrienols differ from the analogous tocopherols by the presence of three double bonds in the hydrophobic side chain.
- Formula (I) The various forms of vitamin E are shown by Formula (I):
- tocopherol in any of the four forms may be used.
- the alpha form of tocopherol is preferred.
- phosphate compound refers to phosphorylated tocopherol, where a covalent bond is formed between an oxygen atom (typically originating from a hydroxyl group) of the tocopherol compound and the phosphorous atom of a phosphate group (PO 4 ).
- the phosphate compound may be a phosphate mono-ester, phosphate di-ester, phosphate tri-ester, pyrophosphate mono-ester, pyrophosphate di-ester, or a salt or derivative thereof, or a combination thereof.
- the di- and tri-esters may comprise the same tocopherol form or different tocopherol forms.
- the “salts” include metal salts such as alkali or alkaline earth metal salts, for example sodium, magnesium, potassium and calcium salts. Sodium and potassium salts are preferred.
- derivatives include phosphate compounds where one or more phosphate protons are replaced by a substituent.
- Some non-limiting examples of derivatives include phosphatidyl derivatives where a phosphate proton is substituted with an amino-alkyl group, sugar derivatives where a phosphate proton is substituted with a sugar such as glucose.
- amino-alkyl group refers to a group comprising an amino (—NH 2 ) group and an alkyl group.
- alkyl refers to straight chain, branched chain or cyclic hydrocarbon groups having from 1 to 8 carbon atoms. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, cyclohexyl, heptyl, and octyl. Phosphatidyl choline derivatives are most preferred.
- the mono-tocopheryl phosphate compound may be selected from the group consisting of mono-(tocopheryl) phosphate, mono-(tocopheryl) phosphate monosodium salt, mono-(tocopheryl) phosphate disodium salt, mono-(tocopheryl) phosphate monopotassium salt and mono-(tocopheryl) phosphate dipotassium salt, and the di-tocopheryl phosphate compound may be selected from the group consisting of di-(tocopheryl) phosphate, di-(tocopheryl) phosphate monosodium salt and di-(tocopheryl) phosphate monopotassium salt.
- These phosphate compounds may be derived from the alpha, beta, gamma or delta form of tocopherol, or a combination thereof.
- the ratio (% w/w) is at least 2:1, within a range of about 4:1 to about 1:4, within a range of about 6:4 to about 8:2.
- the ratio may be about 2:1, about 6:4, or about 8:2.
- the mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound may be present in an amount within a range of about 0.01% w/w to about 10% w/w, within the range of about 0.1% w/w to about 5% w/w, within the range of about 0.1% w/w to about 3% w/w, within the range of about 0.1% w/w to about 2% w/w, within the range of about 0.1% w/w to about 1% w/w or within the range of about 0.1% w/w to about 0.5% w/w, of the total concentration of the composition, or matrix layer.
- the mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound may be present in an amount within a range of about 0.5% w/w to about 1.5% w/w, or in an amount of about 0.1% w/w, of the total concentration of the composition, or matrix layer.
- composition, or matrix layer also comprises a polymer carrier.
- the polymer carrier may comprise natural and synthetic polymers, co-polymers, or terpolymers.
- Natural polymers include rubbers, elastomers, polysaccharides such as cellulose, natural resins such as shellac and amber.
- Synthetic polymers include, for example, acrylates, polyacrylates, polyalkyl acrylates, polyamides, polyesters, polycarbonates, polyimides, polystyrenes, acrylonitrile butadiene styrene, polyacrylonitrile, polybutadiene, poly(butylene terephthalate), poly(ether sulphone), poly(ether)ketones, polyethylene, poly(ethylene glycol), poly(ethylene terphthalate), polypropylene, polytetratfluroethylene, styrene-acrylonitrile resin, poly(trimethylene terephthalate), polyurethanes, polyvinyl butyral, polyvinylchlorides, polyvinylidenedifluoride, povidones, poly(vinyl pyrrolidone), polychloroprene, fluoroelastomers, chloro-sulphonated rubbers, hypromellose, polyolefine elastomer, polyacrylamide, chlor
- Preferred polymer carriers suitable for use in the composition, or matrix layer, of the present invention include acrylates, povidones and siloxanes.
- Particularly preferred polymer carriers include polyvinyl pyrrolidone (e.g. PVP K90, MW 360,000 Da), polysiloxanes, polyalkyl acrylates (e.g. DuroTak) and polymethyl methacrylate (e.g. Eudragit E100).
- the polymer carrier is polyvinyl pyrrolidone.
- the polymer carrier is polymethyl methacrylate.
- the polymer carrier used in the composition, or matrix layer may have sufficient tackiness to enable the transdermal delivery patch to adhere to skin.
- amine-resistant polysiloxanes and combinations thereof can be used in the composition, or matrix layer.
- the polysiloxanes may be synthesized from linear bifunctional and branched polyfunctional oligomers. It has been found that the ratio of both types of oligomers determines the physical properties of the polymers.
- a high tack version should be tacky enough for the transdermal delivery patch to adhere to the surface of skin.
- a medium tack version may not be tacky at all but could be useful by providing a softening effect to other components included in the composition, or matrix layer.
- a silicone oil e.g. dimethicone
- the polymer carrier may be present in an amount within the range of about 30% w/w to about 95% w/w, within the range of about 30% w/w to about 80% w/w, or within the range of about 55% w/w to about 65% w/w, of the total weight of the composition, or matrix layer.
- the polymer carrier may also comprise inert carrier components, such as for example, anti-tacking agents, tackifiers, and plasticizers to achieve appropriate softness, flexibility and “tackiness” for the polymer carrier to enable the composition, or matrix layer, to adhere to the surface of skin, and thus provide consistent delivery.
- inert carrier components such as for example, anti-tacking agents, tackifiers, and plasticizers to achieve appropriate softness, flexibility and “tackiness” for the polymer carrier to enable the composition, or matrix layer, to adhere to the surface of skin, and thus provide consistent delivery.
- anti-tacking agents that are solid with no stickiness property (i.e. low ability to retain solvents upon drying) and that can be mixed well (i.e. do not crystallise upon drying) with the polymer carrier may be suitable. The selection would be based on the polymer-type. Many surfactants are suitable for use as an anti-tacking agent with a polymer carrier. A more specific example of an anti-tacking agent is succinic acid. In specific embodiments, the anti-tacking agent may be present in an amount or less than 1% w/w, up to about 1% w/w, or up to about 5% w/w, of the total weight of the composition, or matrix layer.
- a tackifier or tacking agent
- Tack can be controlled by combining adhesives of varying hardnesses (glass temperature or T g ).
- a tackifier is a polymer which is insoluble in water and composed of a monomer which contains partly or wholly a (meth)acrylic alkyl ester.
- Such types of polymers include, but are not limited to, acrylic, N-butyl-methacrylic copolymer (Primal N580NF, sold by Japan Acrylic Chemical Company, Ltd.), acrylic methyl, acrylic 2-ethylhexyl copolymer (Nikasol TS-6520, sold by Nippon Carbide Industries Company, Ltd), polyacrylic acid (Jurymer AC-IOLPH, sold by Nihon Junyaku Company, Ltd), methacrylic copolymer L (Plastoid L50, sold by Rohm Pharma GmbH), and aminoalkylmethacrylate copolymer E (Plastoid E35L, Plastoid E35M, Plastoid E35H, all sold by Rohm Pharma GmbH).
- Other non-limiting examples include rosin esters, hydrogenated rosins, dipropylene glycol dibenzoate, and/or mixed hydrocarbons, and acrylic copolymers (e.g. Flexbond 150 adhesive by Air Products).
- Plasticizers are additives that increase the plasticity or fluidity of the material to which they are added. Plasticizers may be used in the present invention to soften the final product increasing its flexibility and making it less brittle. Suitable plasticizers include phthalates, esters of polycarboxylic acids with linear or branched aliphatic alcohols of moderate chain length, acetylated monoglycerides, alkyl citrates, triethyl citrate (TEC), acetyl triethyl citrate (ATEC), tributyl citrate (TBC), acetyl tributyl citrate (ATBC), trioctyl citrate (TOC), acetyl trioctyl citrate (ATOC), trihexyl citrate (THC), acetyl trihexyl citrate (ATHC), butyryl trihexyl citrate (BTHC, trihexyl o-butyryl citrate), trimethyl citrate (TMC), methyl laurate,
- Inert carrier components may be present in an amount within the range of about 0.001% w/w to about 50% w/w, within the range of about 0.001% w/w to about 40% w/w, within the range of about 0.001% w/w to about 30% w/w, of the total weight of the composition, or matrix layer.
- the composition, or matrix layer comprises an anti-tacking agent (such as succinic acid) and a plasticizer (such as dibutyl sebacate) in a total amount of about 35% w/w of the total weight of the composition, or matrix layer.
- the amount of polymer carrier and optional inert carrier components present in the composition, or matrix layer will depend on the specific biologically active compound to be administered. Generally, however, these components may be present in an amount within the range of about 50% w/w to about 99% w/w, within the range of about 80% w/w to about 98% w/w, within the range of about 90% w/w to about 98% w/w, of the total weight of the composition, or matrix layer. In one embodiment, the composition, or matrix layer, comprises these components in the amount of about 95% w/w of the total weight of the composition, or matrix layer.
- polymer carrier could be used collectively to refer to the polymer carrier and the inert carrier components.
- composition, or matrix layer may also optionally further comprise one or more excipients (in addition to the inert carrier components discussed above).
- excipients for inclusion in the composition, or matrix layer, of the invention.
- Some examples include, but are not limited to, solvents, thickeners or gelling agents, preservatives, surfactants, stabilizers, buffers, emollients, colours, fragrances, and appearance modifiers.
- any excipients which have been approved for use in pharmaceutical products by the regulatory bodies may be employed in the composition, or matrix layer, of the present invention.
- the amount of a particular excipient or excipients to be used in a composition, or matrix layer, of the present invention would also be appreciated by a person skilled in the art.
- composition, or matrix layer may form part of a transdermal delivery matrix patch. It has been surprisingly found that a transdermal delivery patch comprising this composition, or matrix layer, can effectively administer biologically active compounds.
- biologically active compound refers to any chemical substance that has a biological effect in humans or animals for medical, therapeutic, cosmetic and veterinary purposes, and encompasses pharmaceuticals including drugs, cosmeceuticals, nutraceuticals, and nutritional agents. It will be appreciated that some of biologically active compounds can be classified in more than one of these classes.
- a wide range of biologically active compounds may be delivered with the transdermal delivery patch of the present invention.
- cardiovascular drugs in particular antihypertensive agents (e.g. calcium channel blockers or calcium antagonists) and antiarrhythmic agents; congestive heart-failure pharmaceuticals; inotropic agents; vasodilators; ACE inhibitors; diuretics; carbonic anhydrase inhibitors; cardiac glycosides; phosphodiesterase inhibitors; ⁇ blockers; ⁇ -blockers; sodium channel blockers; potassium channel blockers; ⁇ -adrenergic agonists; platelet inhibitors; angiotensin II antagonists; anticoagulants; thrombolytic agents; treatments for bleeding; treatments for anaemia; thrombin inhibitors; antiparasitic agents; antibacterial agents; insulin; human growth hormone and peptides; vaccines; antiinflammatory agents, in particular non-steroidal antiinflammatory agents (NSAIDs), more particularly COX-2 inhibitors; steroidal antiinflammatory agents; prophyl, and others.
- Suitable biologically active compounds include:
- amino-ester and amino-amide anaesthetics such as benzocaine, chloroprocaine, ***e, reserpine, guanethidine, cyclomethycaine, dimethocaine/larocaine, propoxycaine, procaine/novocaine, proparacaine, tetracaine/amethocaine; articaine, bupivacaine, carticaine, cinchocaine/dibucaine, etidocaine, levobupivacaine, lidocaine/lignocaine, mepivacaine, piperocaine, prilocaine, ropivacaine, trimecaine, propofol, halothane, enflurane barbiturates, benzodiazepines, neostigmine and ketamine
- amiodarone including amiodarone, disopyramide, flecainide acetate, quinidine sulphate, nitroglycerine, ranolazine, amiodarone, isosorbide and alteplase
- doxorubicin including doxorubicin, 6-thioguanine, paclitaxel, docetaxel, camptothecin, megestrol acetate, navelbine, cytarabine, fludarabine, 6-mercaptopurine, 5-fluorouracil, teniposide, vinblastine, vincristine, cisplatin, colchicine, carboplatin, procarbazine and etopside
- alprazolam including alprazolam, amoxapine, bentazepam, bromazepam, clorazipine, clobazam, clotiazepam, diazepam, lorazepam, flunitrazepam, flurazepam, lormetazepam, medazepam, nitrazepam, oxazepam, temazepam, maprotiline, mianserin, nortriptyline, risperidone, sertraline, trazodone, baloperidol, trimipramine maleate fluoxetine, ondansetron, midazolam, chlorpromazine, haloperidol, triazolam, clozapine, fluopromazine, fluphenazine decanoate, fluanisone, perphenazine, pimozide, prochlorperazine, sulpiride, thioridazine, paroxi
- benznidazole clioquinol, decoquinate, diiodohydroxyquinoline, diloxanide furoate, dinitolmide, furzolidone, metronidazole, nimorazole, nitrofurazone, ornidazole, terbinafine, clotrimazole, chloroquine, mefloquine, itraconazole, pyrimethamine, praziquantel, quinacrine, mebendazole and tinidazole
- bromocriptine mesylate including bromocriptine mesylate, levodopa, tolcapone, ropinirole, bromocriptine, hypoglycaemic agents such as sulfonylureas, biguanides, ⁇ -glucosidase inhibitors, thaiazolidinediones, cabergoline, carbidopa and lysuride maleate
- hypoglycaemic agents such as sulfonylureas, biguanides, ⁇ -glucosidase inhibitors, thaiazolidinediones, cabergoline, carbidopa and lysuride maleate
- meoxicam including meoxicam, triamcinolone, cromolyn, nedocromil, hydroxychloroquine, montelukast, zileuton, zafirlukast and meloxicam
- omeprazole including omeprazole, lansoprazole, pantoprazole and ranitidine
- hydrochlorothiazide including amiloride, acetazolamide, furosemide and torsemide
- opioid analgesics including opioid receptor agonists, opioid receptor partial agonists, opioid antagonist or opioid receptor mixed agonist-antagonists; opioid receptor agonists including morphine, depomorphine, etorphine, heroin,
- arylalkanoic acid sub-group of class which includes diclofenac, aceclofenac, acemetacin, alclofenac, bromfenac, etodolac, indometacin, indometacin farnesil, nabumetone, oxametacin, proglumetacin, sulindac and tolmetin; 2-arylpropionic acid (profens) sub-group of class which includes alminoprofen, benoxaprofen, carprofen, dexibuprofen, dexketoprofen, fenbufen, fenoprofen, flunoxaprofen, flurbiprofen, ibuprofen, ibuproxam, indoprofen, ketoprofen, ketorolac, loxoprofen, miroprofen, naproxen, oxaprozin, pirprofen, suprofen, taren
- first generation retinoids such as retinol, retinal, tretinoin (retinoic acid, Retin-A), isotretinoin and alitretinoin
- second generation retinoids such as etretinate and its metabolite acitretin
- third generation retinoids such as tazarotene, bexarotene and adapalene
- adrenocorticotrophic hormone including adrenocorticotrophic hormone (ACTH), antidiruetic hormone (vasopressin), atrial-nartreuretic factor (ANF), atrial-nartreuretic peptide (ANP), beclomethasone, cortisone, scopolamine, dopamine, epinephrine, catecholamines, cholecystokinin, clomiphene citrate, danazol, dexamethasone, diethylstilbestrol (DES), ethinyl estradiol, fludrocortison, finasteride, follicle stimulating hormone, gastrin, hydroxyprogesterone, growth hormone, insulin, leptin, luteinizing hormone, medroxyprogesterone acetate, mestranol, quinestrol, methyltestosterone, nandrolone, norethindrone, norethisterone, norgestrel, estradio
- atorvastatin including atorvastatin, fluvastatin, lovastatin, nystatin, rosuvastatin, pravastatin, orlistat and simvastatin
- levetiracetam including levetiracetam, levitiracetam and donepezil
- tramadol including tramadol, tramadol hydrochloride, allopurinol, calcitriol, cilostazol, soltalol, urasodiol bromperidol, droperidol, flupenthixol decanoate, albuterol, albuterol sulphate, carisoprodol, chlobetasol, ropinirol, labetalol, and methocarbamol
- amioderone including amioderone, fluticasone, spironolactone, prednisone, triazodone, desoximetasone, methyl prednisdone, benzonatate nabumetone and buspirone
- vaccines comprising toxoids (inactivated toxic compounds); proteins, protein subunits and polypeptides; polynucleotides such as DNA and RNA; conjugates; adjuvants such as saponins, virosomes, inorganic and organic adjuvants, for example zostavax
- coenzyme Q 10 or ubiquinone
- ubiquinol or resveratrol a carotenoid such as ⁇ , ⁇ , or ⁇ -carotene, lycopene, lutein, zeaxanthin and astaxanthin
- a phytonutrient such as lycopene, lutein and seaxanthin
- an unsaturated fatty acid such as linoleic acid, conjugated linoleic acid, linolenic acid, omega-3 fatty acids including but not limited to docosahexaenoic acid (DHA) and eicosapentaeonic acid (EPA) and their glycerol-esters
- fat-soluble vitamins including vitamin D (D2, D3 and their derivatives), vitamin E ( ⁇ , ⁇ , ⁇ , ⁇ -tocopherols, or ⁇ , ⁇ , ⁇ , ⁇ -tocotrienols), vitamin A (retinol, retinal, retinoic acid
- Particularly preferred biologically active compounds include alprazolam, donepazil, rispiredone, lorazepam, nicotine, lidocaine, diclofenac, felodipine, insulin, ketoralac, prilocaine, halobetasol, hydrocortisol, opioids such as oxycodone or dihydrohydroxycodeinone (oxycodone base).
- nutraceutically, nutraceutically or cosmeceutically acceptable derivatives includes, but is not limited to, pharmaceutically, nutraceutically or cosmeceutically acceptable salts, esters, salts of such esters, ethers, or any other derivative including prodrugs and metabolites, which upon administration to a subject (e.g. patient, human or animal) in need is capable of providing, directly or indirectly, a biologically active compound as otherwise described herein.
- nutraceutically, nutraceutically or cosmeceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically, nutraceutically or cosmeceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically, nutraceutically or cosmeceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19, 1977.
- Examples of pharmaceutically, nutraceutically or cosmeceutically acceptable nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hernisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
- alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate, and aryl sulfonate.
- ester refers to esters which are hydrolysed in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
- Suitable ester groups include, for example, those derived from pharmaceutically, nutraceutically or cosmeceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
- esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
- prodrugs refers to those prodrugs of the biologically active compounds which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.
- the present invention is further not limited solely to the administration of one biologically active compound: more than one biologically active compound or other therapeutic compounds may be incorporated into the composition, or matrix layer.
- the biologically active compound may be present in a therapeutically effective amount, that is, an amount necessary to achieve a desired therapeutic effect.
- the biologically active compound will be present in an amount within the range of about 0.1% w/w to about 30% w/w, within the range of about 0.1% w/w to about 20% w/w, within the range of about 0.1% w/w to about 10% w/w, of the total concentration of the composition, or matrix layer.
- the matrix layer will have a biologically active compound concentration within the range of about 3.0% w/w to about 15.0% w/w of the total concentration of the composition, or matrix layer.
- the ratio of biologically active compound:TP may be within the range of about 5:5 to about 5:0.5, with the most preferred value preferably being about 5:1.
- the polymer carrier:[biologically active compound and TP] may be within the range of about 1:1 to about 3:1, with preferred values preferably being within the range of about 7:6 to about 7:3.
- composition, or matrix layer may form part of a transdermal delivery matrix patch.
- the transdermal delivery patch may be prepared by a variety of techniques.
- One technique involves combining the polymer carrier and any inert carrier components such as an anti-tacking agent and/or plasticizer with a suitable solvent (e.g. 50% water, 50% ethanol). This is combined with a dispersion comprising the biologically active compound and the mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound, and is stirred until complete homogenisation is achieved.
- the composition may then be placed in a suitable mould and dried.
- the composition may be dried by heating up to about 90° C., preferably for 0.5 to 24 hours.
- formulating and/or drying may be conducted at a temperature within the range of about 30° C. to about 90° C. It has been found that formulating and/or drying at a temperature of about 75° C. results in better delivery of the biologically active compound.
- the composition may be cast on a surface (e.g. a roller) and then dried under heat.
- composition comprising a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound and a polymer carrier is suitable for use as a matrix layer.
- the matrix layer may be a solid or semi-solid layer.
- the transdermal delivery patch usually would also comprise a backing layer.
- the backing layer acts as a support or substrate for the composition, or matrix layer.
- the backing layer When preparing a transdermal delivery patch using a mould, the backing layer would be placed in the mould before addition of the composition, or matrix layer.
- the composition, or matrix layer essentially has two surfaces: a first surface and a second surface opposite the first surface, where the first surface is in contact with the backing layer and the second surface being adapted to be in diffusional contact with the skin of a subject.
- the subject may be a human or animal.
- the backing layer is occlusive or impermeable to protect the composition, or matrix layer, from the outer environment.
- a non-occlusive backing layer could also be used, so long as the packaging of the transdermal delivery patch is fully occlusive to prevent degradation of the composition, or matrix layer.
- An occlusive backing layer is preferred.
- the backing layer may be of any thickness, however in the art, backing layers typically have a thickness of about 0.0005 inches to about 0.01 inches.
- the transdermal delivery patch may further comprise a liner which is a removable protective or impermeable layer, usually but not necessarily rendered “non-stick” so as not to stick to the composition, or matrix layer.
- the liner which may also be referred to as the release liner, protects the transdermal delivery patch during storage. During use, the release liner is to be removed.
- the liner may be made from the same material as the backing layer, however it may also be a metal foil, Mylar (registered trademark), polyethylene terephthalate, siliconized polyester, fumed silica in silicone rubber, polytretrafluoroethylene, cellophane, siliconized paper, aluminized paper, polyvinyl chloride film, composite foils or films containing polyester such as polyester terephthalate, polyester or aluminized polyester, polytetrafluoroethylene, polyether block amide copolymers, polyethylene methyl methacrylate block copolymers, polyurethanes, polyvinylidene chloride, nylon, silicone elastomers, rubber-based polyisobutylene, styrene, styrene-butadiene, and styrene-isoprene copolymers, polyethylene, and polypropylene.
- Mylar registered trademark
- polyethylene terephthalate siliconized polyester
- the release liner may be of any thickness, however in the art, release liners typically have a thickness of about 0.01 mm to about 2 mm.
- the transdermal delivery patch may also comprise an adhesive layer.
- the adhesive layer may be an additional layer to the composition, or matrix layer, or may be included on the outer margin of the backing layer where the backing layer extends beyond the edges of the composition, or matrix layer.
- Polymeric adhesives useful for transdermal patches include polyacrylate polymers, rubber-based adhesives and polysiloxane adhesives. These types of materials, as well as others, are described by Van Norstrand (The Handbook of Pressure Sensitive Adhesive Technology Second Edition 1989), which is hereby incorporated by reference.
- Examples of commercially available adhesives include, but are not limited to, polyacrylate adhesives sold under the trademarks DUROTAK (registered trademark) by National Starch and Chemical Corporation, Bridgewater, N.J., as well as GELVA-MULTIPOLYMER SOLUTION (registered trademark) by Cytek Surface Specialties, Smyrna, Ga.
- transdermal delivery patch comprising a composition, or matrix layer, which comprises a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound and a polymer carrier.
- Transdermal delivery options for include, for example, topical creams and gels, and skin patches.
- Creams and gels may present difficulties with compliance and dosage control, and may be considered messy or unpleasant by patients.
- a “reservoir” patch essentially has a liquid or gel compartment containing the drug solution or suspension separated by a membrane and a layer of adhesive.
- the drug dispersion is present in a semi-solid or solid layer, which may or may not also comprise the adhesive material.
- Reservoir patches overcome some of the dosage difficulties with topical creams and gels, however the delivery may be uneven or inconsistent, and there is some risk of perforation of the reservoir.
- An additional issue relates to delivery of prescribed drugs which may be addictive and subject to abuse.
- Gels, creams and reservoir patches provide limited barriers to extraction of the drug substance, whereas incorporation of the drug substance within a composition, or matrix layer, represents a significant, if not almost impossible barrier to extraction of the drug substance.
- Transdermal delivery provides a non-invasive way of potentially achieving sustained steady state delivery.
- the presence of a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound is considered to enhance the skin permeation of the biologically active compound. It has also been found that the components of the composition, or matrix layer, do not formulate well together without the presence of a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound. It has also been found that the presence of a phosphate compound of tocopherol will act to reduce skin irritation caused by many the biologically active compounds.
- FIG. 1 is a schematic diagram of a transdermal delivery patch of one embodiment of the present invention
- FIG. 2 is a graph comparing the delivery of oxycodone using a transdermal delivery patches of the present invention prepared with different drying regimes;
- FIG. 3 is a graph comparing the delivery of oxycodone using transdermal delivery patches of the present invention prepared with and without a glue layer;
- FIG. 4 is a graph comparing the delivery of oxycodone using transdermal delivery patches of the present invention prepared with and without an occlusive backing layer;
- FIG. 5 is a graph showing the results of pharmacokinetic testing conducted after application of transdermal delivery patches of the present invention.
- FIG. 6 is a graph showing the results of pharmacodynamic testing conducted after application of transdermal delivery patches of the present invention.
- FIG. 7 is a graph comparing the delivery of oxycodone using transdermal delivery patches of the present invention comprising different plasticisers
- FIG. 8 is a graph comparing the delivery of oxycodone using transdermal delivery patches of the present invention comprising different plasticisers and polymer carriers;
- FIG. 9 is a graph showing the average change in blood glucose after application of transdermal delivery patches of the present invention to each of the animals;
- FIG. 10 is a graph showing the area under the curve of the graph of FIG. 9 ;
- FIGS. 11 and 12 are graphs comparing the deposition in skin of two diclofenac transdermal delivery patches.
- FIG. 13 is a graph comparing the permeation of two lidocaine transdermal delivery patches.
- the components were dissolved in a solvent solution (acetone:isopropanol:ethyl alcohol 60:6.6:33.5 by % weight).
- the resulting solution was then poured into individual casts (containing suitable backing layers) at room temperature and the solvent was allowed to evaporate at 75° C. for 1.5 hours.
- composition, or matrix layer, components could be combined at a suitable temperature to produce a homogeneous molten mass.
- the molten mass can then be cast on a cold surface (for example, a rotating mill with a suitable backing layer, or sheet, thereon) and allowed to solidify. Individual transdermal delivery patches of varying sizes may then be cut.
- FIG. 1 shows an example of a transdermal delivery patch of one embodiment of the present invention.
- Transdermal delivery patches were constructed by dissolving 20% w/w solid mixture of Eudragit E100 granules, dibutyl sebacate, succinic acid (the components other than TPM and oxycodone in the composition, or matrix layer, may collectively be referred to as the “polymer carrier”); a combination of mono-(tocopheryl) phosphate and di-(tocopheryl) phosphate in a ratio of 6:4 (TPM); and oxycodone base in 60:6.6:33.4 acetone/isopropyl alcohol/ethyl alcohol.
- the mixture was then transferred into 6 cm 2 circular aluminium cast-lined on the underside with polyester backing (1.66 mil, 3M ScotchpakTM, 3M, MN) and the solvent evaporated in an oven at either 45° C. overnight or 75° C. for 1.5 hours.
- the glue was DuroTak adhesive and in this example succinic acid was omitted from the formulation.
- Oxycodone transdermal delivery patches were made according to Example 1 (small scale), testing the variable of the two different heating regimes.
- the transdermal delivery patches were adhered to full thickness human skin applied to a Franz cell with PBS as the receiver solution. Time points were taken at 18, 22, 24, 42, 44, 68 and 75 hours and the receiver solution was tested by HPLC to determine the concentration of oxycodone which had passed through the skin.
- the results outline in FIG. 2 show that the transdermal delivery patch manufactured using the higher (accelerated) drying temperature has increased transdermal delivery properties compared with the transdermal delivery patch manufactured with drying at a lower temperature.
- Transdermal delivery patches were manufactured and the receiver solution tested as in Example 3, with testing time points of 0.5, 1, 3, 4 and 20 hours.
- transdermal delivery patches were manufactured and the receiver solution tested as in Examples 3 and 4, at time points 1, 2, 3, 4 and 5 hours.
- This example compares plasma PK parameters using Patch Nos. 1, 2, 4 and 5 from Example 2.
- Transdermal delivery patches were cut from the polyester backing and adhered to the shaved and washed back of a 10-12 week old male Sprague-Dawley rat with a 6 ⁇ 7 cm Tegaderm HPTM (3M, MN) adhesive dressing either with the backing layer in place or removed (see Table below). Tegaderm serves to hold the occlusive backing layer in place, or if the backing layer is absent, holds the transdermal delivery patch itself in place.
- the PK parameters quantified were:
- AUC 0-4 The area under the curve between 0 and 4 hours (the duration of the experiment was 4 hours) and is a measure of the total amount of drug delivered.
- Rats were prepared and dosed similar to Example 6 using Patch Nos. 1, 3 and 5 from Example 2.
- AUC This is a measure of the total analgesia over the observation period as measured by the area under the curve between 0 and 4 hour, and is useful for comparing the response to different treatments.
- Example 2 The following formulations were prepared as outlined in Example 2. Formulation 1 was cast onto a die and Formulation 2 was cast onto a plate. The percentages below reflect the composition when the patch is dry.
- Formulation 1 (1% T80, dbs) % w/w Eudragit 100 60.59 DBS 26.28 Succinic acid 5.46 Oxycodone 5.56 Tocopheryl phosphate 0.67 Di-tocopheryl phosphate 0.44 Tween 80 1.00 100.00
- Formulation 2 (3% ML, 25% T) % w/w Eudragit 100 60.59 Transcutol 24.28 Succinic acid 5.46 Oxycodone 5.56 Tocopheryl phosphate 0.67 Di-tocopheryl phosphate 0.44 Methyl laurate 3.00 100.00
- transdermal delivery patches were adhered to full thickness human skin applied to a Franz cell with PBS as the receiver solution. Time points were taken at 1, 2, and 4 hours and the receiver solution was tested by HPLC to determine the concentration of oxycodone which had passed through the skin.
- Example 2 The following formulations were prepared as in Example 1, however with the composition was cast onto a flat surface or plate instead of a die.
- transdermal delivery patches were adhered to full thickness human skin applied to a Franz cell with PBS as the receiver solution. Time points were taken at 1, 2, and 4 hours and the receiver solution was tested by HPLC to determine the concentration of oxycodone which had passed through the skin.
- transdermal delivery patches of the present invention were tested against a positive control gel.
- the table below sets out the composition of the composition, or matrix layer, in each of the four transdermal delivery patches.
- the polyvinylpyrrolidone was found to provide the composition, or matrix layer, with sufficient “tackiness” to avoid the need to include any inert carrier components.
- the dry weight of each transdermal delivery patch was 60 mg.
- compositions, or matrix layer were dissolved in a solvent solution (50% water, 50% ethanol). The resulting solution was then poured into individual casts (containing suitable backing layers) at room temperature and the solvent was allowed to evaporate at 75° C. for 1.5 hours.
- solvent solution 50% water, 50% ethanol
- the study was a cross-over design to test the effect of transdermal delivery patches of the present invention compared to the gel.
- each animal received four of the five treatments across the course of the study.
- the animals were male and 10-12 weeks of age.
- Each treatment group was 11 animals. All animals were >300 g in weight, and had circulating glucose concentrations of >10 mmol/L in the fasted state (mean fasted glucose concentration was 21.37 ⁇ 0.85 mmol/L).
- the key endpoint of the study was blood glucose levels during a 5-hour insulin tolerance test, conducted as described below.
- STZ streptozotocin
- sodium citrate buffer 0.1 mol/L, pH 4.5
- Rats were considered diabetic and included in the study if their blood glucose was greater than 16 mmol/L 24 hours after the STZ injection.
- blood glucose measurements were made by obtaining a spot sample from tail tipping. Animals were left for 5 days following STZ administration prior to testing.
- the animals were anaesthetised and ⁇ 30 cm 2 of fur was shaved from the back, avoiding any damage to the skin that could enhance absorption of the formulations.
- the gel was applied at a dose of 12 mg/cm 2 across the shaved area.
- the transdermal delivery patches were adhered to the shaved area and protected with the application of a tegaderm dressing.
- the insulin tolerance tests were performed 24 hours after removing the fur. Following each treatment, the animals were allowed to recover for 3 days before the next treatment.
- the gel and the transdermal delivery patches caused significant reductions in blood glucose concentrations in the diabetic rats (see FIGS. 9 and 10 ). Blood glucose was significantly reduced (p ⁇ 0.05) from starting values 30 min after application and remained lowered for the duration of the experiment. There was no statistically significant difference in the reduction of blood glucose between the patches and gel tested here, as demonstrated by the area under the curve (see FIG. 10 ).
- the transdermal delivery patches appear efficacious for the delivery of insulin, however, a transdermal delivery patch provides the many advantages described herein over a gel or other methods of delivery.
- Diclofenac diethylamine transdermal delivery patches were prepared having the following composition:
- the diclofenac diethylamine transdermal delivery patches had a surface area of 120 cm 2 .
- Transdermal delivery patches were cut into circular discs (7 cm 2 ) and placed over rat skin.
- Receptor solution was 12 ml and had an effective surface with the skin equal to about 1.76 cm 2 .
- skin about 7 cm 2 was removed, the surface cleaned (excess gel) and extracted with 10 ml solvent.
- Lidocaine transdermal delivery patches were prepared having the following composition:
- the lidocaine transdermal delivery patches had a surface area of 120 cm 2 .
- Transdermal delivery patches were cut into circular discs (7 cm 2 ) and placed over rat skin.
- Receptor solution was 12 ml and had an effective surface with the skin equal to about 1.76 cm 2 .
- skin about 7 cm 2 was removed, the surface cleaned (excess gel) and extracted with 10 ml solvent.
Abstract
A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.
Description
- The present invention relates to a composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, and a transdermal delivery patch comprising the composition, or matrix layer.
- In this specification where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date, publicly available, known to the public, part of common general knowledge; or known to be relevant to an attempt to solve any problem with which this specification is concerned.
- Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans and animals.
- Drug delivery technologies have been developed to improve bioavailability, safety, duration, onset or release, of the pharmaceutical compound.
- When developing drug delivery technologies, problems likely to be encountered include compatibility of the drug delivery system and the pharmaceutical compound, maintaining an adequate and effective duration, potential for side effects, and meeting patient convenience and compliance. As a consequence, many drug delivery technologies fall short of desired improvements and requirements.
- Accordingly, there is still a need for alternate delivery systems that effectively deliver drugs and other biologically active compounds.
- The present invention relates to a composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, and a transdermal delivery patch comprising the composition, or matrix layer.
- Accordingly, a first aspect of the present invention provides a matrix layer for use in a transdermal delivery patch for administration of a biologically active compound, the matrix layer comprising a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound and a polymer carrier wherein the polymer carrier is present in an amount within the range of about 30% w/w to about 95% w/w.
- The present invention also provides use of the composition, or matrix layer, in a transdermal delivery patch for administration of a biologically active compound.
- It has surprisingly been found that biologically active compounds can be effectively administered using a transdermal delivery patch.
- A second aspect of the present invention provides a transdermal delivery patch for administration of a biologically active compound comprising the composition, or matrix layer. The composition, or matrix layer, may be a solid or semi-solid layer. The transdermal delivery patch may comprise further layers.
- A third aspect of the present invention provides a method for preparing a transdermal delivery patch for administration of a biologically active compound comprising the steps of:
- (i) combining a polymer carrier and optional inert carrier components with a suitable solvent;
- (ii) combining (i) with a dispersion comprising a biologically active compound and a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound;
- (iii) stirring (ii) until complete homogenisation is achieved;
- (iv) placing the composition of (iii) in a suitable mould or casting the composition of (iii) on a surface;
- (v) drying the composition under heat.
- The present invention relates to a composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier. The composition, or matrix layer, may form part of a transdermal delivery matrix patch. It has been surprisingly found that a transdermal delivery patch comprising this composition, or matrix layer, can effectively administer biologically active compounds.
- The composition, or matrix layer, comprises a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound.
- Vitamin E exists in eight different forms, namely four tocopherols and four tocotrienols. All feature a chroman ring, with a hydroxyl group that can donate a hydrogen atom to reduce free radicals and a hydrophobic side chain which allows for penetration into biological membranes. Such derivatives of vitamin E may be classified as “hydroxy chromans”. Both tocopherols and tocotrienols occur in alpha, beta, gamma and delta forms, determined by the number and location of methyl groups on the chroman ring. The tocotrienols differ from the analogous tocopherols by the presence of three double bonds in the hydrophobic side chain. The various forms of vitamin E are shown by Formula (I):
-
R1 R2 R3 α-tocopherol CH3 CH3 CH3 α-tocotrienol β-tocopherol CH3 H CH3 β-tocotrienol γ-tocopherol H CH3 CH3 γ-tocotrienol δ-tocopherol H H CH3 δ-tocotrienol - In the present invention, tocopherol in any of the four forms may be used. The alpha form of tocopherol is preferred.
- The term “phosphate compound” refers to phosphorylated tocopherol, where a covalent bond is formed between an oxygen atom (typically originating from a hydroxyl group) of the tocopherol compound and the phosphorous atom of a phosphate group (PO4).
- The phosphate compound may be a phosphate mono-ester, phosphate di-ester, phosphate tri-ester, pyrophosphate mono-ester, pyrophosphate di-ester, or a salt or derivative thereof, or a combination thereof. The di- and tri-esters may comprise the same tocopherol form or different tocopherol forms.
- The “salts” include metal salts such as alkali or alkaline earth metal salts, for example sodium, magnesium, potassium and calcium salts. Sodium and potassium salts are preferred.
- The “derivatives” include phosphate compounds where one or more phosphate protons are replaced by a substituent. Some non-limiting examples of derivatives include phosphatidyl derivatives where a phosphate proton is substituted with an amino-alkyl group, sugar derivatives where a phosphate proton is substituted with a sugar such as glucose.
- The term “amino-alkyl group” refers to a group comprising an amino (—NH2) group and an alkyl group. The term “alkyl” refers to straight chain, branched chain or cyclic hydrocarbon groups having from 1 to 8 carbon atoms. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, cyclohexyl, heptyl, and octyl. Phosphatidyl choline derivatives are most preferred.
- The mono-tocopheryl phosphate compound may be selected from the group consisting of mono-(tocopheryl) phosphate, mono-(tocopheryl) phosphate monosodium salt, mono-(tocopheryl) phosphate disodium salt, mono-(tocopheryl) phosphate monopotassium salt and mono-(tocopheryl) phosphate dipotassium salt, and the di-tocopheryl phosphate compound may be selected from the group consisting of di-(tocopheryl) phosphate, di-(tocopheryl) phosphate monosodium salt and di-(tocopheryl) phosphate monopotassium salt. These phosphate compounds may be derived from the alpha, beta, gamma or delta form of tocopherol, or a combination thereof.
- When a combination of a mono-phosphate ester and a di-phosphate ester, that is a mono-(tocopheryl) phosphate and di-(tocopheryl) phosphate (which may in some instances herein be referred to as tocopheryl phosphate mixture or simply “TPM”), the ratio (% w/w) is at least 2:1, within a range of about 4:1 to about 1:4, within a range of about 6:4 to about 8:2. The ratio may be about 2:1, about 6:4, or about 8:2.
- The mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound may be present in an amount within a range of about 0.01% w/w to about 10% w/w, within the range of about 0.1% w/w to about 5% w/w, within the range of about 0.1% w/w to about 3% w/w, within the range of about 0.1% w/w to about 2% w/w, within the range of about 0.1% w/w to about 1% w/w or within the range of about 0.1% w/w to about 0.5% w/w, of the total concentration of the composition, or matrix layer. In some embodiments, the mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound may be present in an amount within a range of about 0.5% w/w to about 1.5% w/w, or in an amount of about 0.1% w/w, of the total concentration of the composition, or matrix layer.
- The composition, or matrix layer, also comprises a polymer carrier.
- The polymer carrier may comprise natural and synthetic polymers, co-polymers, or terpolymers.
- Natural polymers include rubbers, elastomers, polysaccharides such as cellulose, natural resins such as shellac and amber.
- Synthetic polymers include, for example, acrylates, polyacrylates, polyalkyl acrylates, polyamides, polyesters, polycarbonates, polyimides, polystyrenes, acrylonitrile butadiene styrene, polyacrylonitrile, polybutadiene, poly(butylene terephthalate), poly(ether sulphone), poly(ether)ketones, polyethylene, poly(ethylene glycol), poly(ethylene terphthalate), polypropylene, polytetratfluroethylene, styrene-acrylonitrile resin, poly(trimethylene terephthalate), polyurethanes, polyvinyl butyral, polyvinylchlorides, polyvinylidenedifluoride, povidones, poly(vinyl pyrrolidone), polychloroprene, fluoroelastomers, chloro-sulphonated rubbers, hypromellose, polyolefine elastomer, polyacrylamide, chlorinated polyethylene, polyethersulphone, nylon, liquid crystal polymers, polyethylene terephthalate (PET), polyphenylsulphone, polypthalaminepolyvinyl alcohol derivatives, poly ethylene glycols, ethylene vinyl acetate, polymethyl methacrylate, cellulose derivatives such as ethyl cellulose, hydroxyl propyl methyl cellulose, sugar derivatives (gums) including derivatives of sorbitol and mannitol, silicone oil and silicone oil derivatives, polysiloxanes including amine-resistant polysiloxanes, and siloxanes.
- Preferred polymer carriers suitable for use in the composition, or matrix layer, of the present invention include acrylates, povidones and siloxanes. Particularly preferred polymer carriers include polyvinyl pyrrolidone (e.g. PVP K90, MW 360,000 Da), polysiloxanes, polyalkyl acrylates (e.g. DuroTak) and polymethyl methacrylate (e.g. Eudragit E100). In one embodiment, the polymer carrier is polyvinyl pyrrolidone. In an alternate embodiment, the polymer carrier is polymethyl methacrylate.
- The polymer carrier used in the composition, or matrix layer, may have sufficient tackiness to enable the transdermal delivery patch to adhere to skin. For instance, amine-resistant polysiloxanes and combinations thereof can be used in the composition, or matrix layer. A combination of a polysiloxane of medium tack and a polysiloxane of high tack is used would be most suitable. The polysiloxanes may be synthesized from linear bifunctional and branched polyfunctional oligomers. It has been found that the ratio of both types of oligomers determines the physical properties of the polymers. More polyfunctional oligomers result in a more cross-linked polymer with a higher cohesion and a reduced tack, less polyfunctional oligomers result in a higher tack and a reduced cohesion. A high tack version should be tacky enough for the transdermal delivery patch to adhere to the surface of skin. A medium tack version, on the other hand, may not be tacky at all but could be useful by providing a softening effect to other components included in the composition, or matrix layer. To increase the adhesive power of the composition, or matrix layer, a silicone oil (e.g. dimethicone) could be added.
- The polymer carrier may be present in an amount within the range of about 30% w/w to about 95% w/w, within the range of about 30% w/w to about 80% w/w, or within the range of about 55% w/w to about 65% w/w, of the total weight of the composition, or matrix layer.
- The polymer carrier may also comprise inert carrier components, such as for example, anti-tacking agents, tackifiers, and plasticizers to achieve appropriate softness, flexibility and “tackiness” for the polymer carrier to enable the composition, or matrix layer, to adhere to the surface of skin, and thus provide consistent delivery.
- For polymers which are naturally “tacky” and may need anti-tackiness to have an appropriate consistency, anti-tacking agents that are solid with no stickiness property (i.e. low ability to retain solvents upon drying) and that can be mixed well (i.e. do not crystallise upon drying) with the polymer carrier may be suitable. The selection would be based on the polymer-type. Many surfactants are suitable for use as an anti-tacking agent with a polymer carrier. A more specific example of an anti-tacking agent is succinic acid. In specific embodiments, the anti-tacking agent may be present in an amount or less than 1% w/w, up to about 1% w/w, or up to about 5% w/w, of the total weight of the composition, or matrix layer.
- In order to enhance the ability of the composition, or matrix layer, to adhere to the surface of skin, it may optionally contain a tackifier (or tacking agent). Tack can be controlled by combining adhesives of varying hardnesses (glass temperature or Tg). Typically, a tackifier is a polymer which is insoluble in water and composed of a monomer which contains partly or wholly a (meth)acrylic alkyl ester. Such types of polymers include, but are not limited to, acrylic, N-butyl-methacrylic copolymer (Primal N580NF, sold by Japan Acrylic Chemical Company, Ltd.), acrylic methyl, acrylic 2-ethylhexyl copolymer (Nikasol TS-6520, sold by Nippon Carbide Industries Company, Ltd), polyacrylic acid (Jurymer AC-IOLPH, sold by Nihon Junyaku Company, Ltd), methacrylic copolymer L (Plastoid L50, sold by Rohm Pharma GmbH), and aminoalkylmethacrylate copolymer E (Plastoid E35L, Plastoid E35M, Plastoid E35H, all sold by Rohm Pharma GmbH). Other non-limiting examples include rosin esters, hydrogenated rosins, dipropylene glycol dibenzoate, and/or mixed hydrocarbons, and acrylic copolymers (e.g. Flexbond 150 adhesive by Air Products).
- Plasticizers are additives that increase the plasticity or fluidity of the material to which they are added. Plasticizers may be used in the present invention to soften the final product increasing its flexibility and making it less brittle. Suitable plasticizers include phthalates, esters of polycarboxylic acids with linear or branched aliphatic alcohols of moderate chain length, acetylated monoglycerides, alkyl citrates, triethyl citrate (TEC), acetyl triethyl citrate (ATEC), tributyl citrate (TBC), acetyl tributyl citrate (ATBC), trioctyl citrate (TOC), acetyl trioctyl citrate (ATOC), trihexyl citrate (THC), acetyl trihexyl citrate (ATHC), butyryl trihexyl citrate (BTHC, trihexyl o-butyryl citrate), trimethyl citrate (TMC), methyl laurate, lauric acid, lauryl lactate, lauryl alcohol, alkyl sulphonic acid phenyl ester, diethylene glycol monoethyl ether, bis(2-ethylhexyl) phthalate (DEHP), diisooctyl phthalate (DIOP), bis(n-butyl)phthalate (DnBP, DBP), diisobutyl phthalate (DIBP), bis(2-ethylhexyl)adipate (DEHA), dimethyl adipate (DMAD), monomethyl adipate (MMAD), dioctyl adipate (DOA), ethyl oleate, sorbitan monooleate, glycerol monooleate, dibutyl sebacate (DBS), dibutyl maleate (DBM), diisobutyl maleate (DIBM), benzoates, epoxidized vegetable oils, tris(tromethamine), N-ethyl toluene sulfonamide (o/p ETSA), N-(2-hydroxypropyl) benzene sulfonamide (HP BSA), N-(n-butyl) benzene sulfonamide (BBSA-NBBS), tricresyl phosphate (TCP), tributyl phosphate (TBP), triethylene glycol dihexanoate (3G6, 3GH), tetraethylene glycol diheptanoate (4G7), 1,3-butyleneglycol, dipropylene glycol, PEG400, Span 80, and polyvinylpyrrolidone. Dibutyl sebacate (DBS), sorbitan monooleate, methyl laurate and lauric acid are preferred plasticizers.
- Inert carrier components may be present in an amount within the range of about 0.001% w/w to about 50% w/w, within the range of about 0.001% w/w to about 40% w/w, within the range of about 0.001% w/w to about 30% w/w, of the total weight of the composition, or matrix layer. In one embodiment, the composition, or matrix layer comprises an anti-tacking agent (such as succinic acid) and a plasticizer (such as dibutyl sebacate) in a total amount of about 35% w/w of the total weight of the composition, or matrix layer.
- The amount of polymer carrier and optional inert carrier components present in the composition, or matrix layer will depend on the specific biologically active compound to be administered. Generally, however, these components may be present in an amount within the range of about 50% w/w to about 99% w/w, within the range of about 80% w/w to about 98% w/w, within the range of about 90% w/w to about 98% w/w, of the total weight of the composition, or matrix layer. In one embodiment, the composition, or matrix layer, comprises these components in the amount of about 95% w/w of the total weight of the composition, or matrix layer.
- It should be noted that, in some instances herein, the term “polymer carrier” could be used collectively to refer to the polymer carrier and the inert carrier components.
- The composition, or matrix layer, may also optionally further comprise one or more excipients (in addition to the inert carrier components discussed above).
- A person skilled in the art of the invention would appreciate what are suitable excipients for inclusion in the composition, or matrix layer, of the invention. Some examples include, but are not limited to, solvents, thickeners or gelling agents, preservatives, surfactants, stabilizers, buffers, emollients, colours, fragrances, and appearance modifiers. It will be appreciated that any excipients which have been approved for use in pharmaceutical products by the regulatory bodies may be employed in the composition, or matrix layer, of the present invention. The amount of a particular excipient or excipients to be used in a composition, or matrix layer, of the present invention would also be appreciated by a person skilled in the art.
- The composition, or matrix layer, may form part of a transdermal delivery matrix patch. It has been surprisingly found that a transdermal delivery patch comprising this composition, or matrix layer, can effectively administer biologically active compounds.
- The term “biologically active compound” refers to any chemical substance that has a biological effect in humans or animals for medical, therapeutic, cosmetic and veterinary purposes, and encompasses pharmaceuticals including drugs, cosmeceuticals, nutraceuticals, and nutritional agents. It will be appreciated that some of biologically active compounds can be classified in more than one of these classes.
- A wide range of biologically active compounds may be delivered with the transdermal delivery patch of the present invention. Examples include, but are not limited to, cardiovascular drugs, in particular antihypertensive agents (e.g. calcium channel blockers or calcium antagonists) and antiarrhythmic agents; congestive heart-failure pharmaceuticals; inotropic agents; vasodilators; ACE inhibitors; diuretics; carbonic anhydrase inhibitors; cardiac glycosides; phosphodiesterase inhibitors; α blockers; β-blockers; sodium channel blockers; potassium channel blockers; β-adrenergic agonists; platelet inhibitors; angiotensin II antagonists; anticoagulants; thrombolytic agents; treatments for bleeding; treatments for anaemia; thrombin inhibitors; antiparasitic agents; antibacterial agents; insulin; human growth hormone and peptides; vaccines; antiinflammatory agents, in particular non-steroidal antiinflammatory agents (NSAIDs), more particularly COX-2 inhibitors; steroidal antiinflammatory agents; prophylactic antiinflammatory agents; antiglaucoma agents; mast cell stabilisers; mydriatics; agents affecting the respiratory system; allergic rhinitis pharmaceuticals; alpha-adrenergic agonists; corticosteroids; chronic obstructive pulmonary disease pharmaceuticals; xanthine-oxidase inhibitors; antiarthritis agents; gout treatments; autacoids and autacoid antagonists; antimycobacterial agents; antifungal agents; antiprotozoal agents; anthelmintic agents; antiviral agents especially for respiratory, herpes, cyto-megalovirus, human immunodeficiency virus and hepatitis infections; treatments for leukemia and kaposi's sarcoma; pain management agents in particular opioids, anaesthetics and analgesics; neuroleptics; sympathomimetic pharmaceuticals; adrenergic agonists; drugs affecting neurotransmitter uptake or release; anticholinergic pharmaceuticals; antihaemorrhoid treatments; agents to prevent or treat radiation or chemotherapeutic effects; liopgenisis drugs; fat reducing treatments; anti-obesity peptides; antiobesity agents such as lipase inhibitors; sympathomimetic agents; treatments for gastric ulcers and inflammation such as proton pump inhibitors; prostaglandins; VEGF inhibitors; antihyperlipidemic agents, in particular statins; drugs that affect the central nervous system (CNS) such as antipsychotic, antiepileptic and antiseizure drugs (anticonvulsants), psychoactive drugs, stimulants, antianxiety and hypnotic drugs, antidepressant drugs; antiparkinson's pharmaceuticals; hormones and fragments thereof such as sex hormones; growth hormone antagonists; gonadotropin releasing hormones and analogues thereof; steroid hormones and their antagonists; selective estrogen modulators; growth factors; antidiabetic pharmaceuticals such as insulin, insulin fragments, insulin analogues, glucagon-like peptides and hypoglycaemic agents; H1, H2, H3 and H4 antihistamines; peptide, protein, polypeptide, nucleic acids and oligonucleotide pharmaceuticals; analogues, fragments and variants of natural proteins, polypeptides, oligonucleotides and nucleic acids and such like compounds; agents used to treat migraine headaches; asthma pharmaceuticals; cholinergic antagonists; glucocorticoids; androgens; antiandrogens; inhibitors of adrenocorticoid biosynthesis; osteoporosis treatments such as biphosphonates; antithyroid pharmaceuticals; suncreens, sun protectants and filters; cytokine agonists; cytokine antagonists; anticancer drugs; antialzheimer drugs; HMGCoA reductase inhibitors; fibrates; cholesterol absorption inhibitors; HDL cholesterol elevating agents; triglyceride reducing agents; antiageing or antiwrinkle agents; precursor molecules for the generation of hormones; proteins such as collagen and elastin; antibacterial agents; anti acne agents; antioxidants; hair treatments and skin whitening agents; suncreens, sun protectants and filters; variants of human apolipoprotein; precursor molecules for generation of hormones; proteins and peptides thereof; amino acids; plant extracts such as grape seed extract; DHEA; isoflavones; nutritional agents including vitamins, phytosterols and iridoid glycosides, sesquiterpene lactones, terpenes, phenolic glycosides, triterpenes, hydroquinone derivatives, phenylalkanones; antioxidants such as retinol and other retinoids including retinoic acid and co enzyme Q10; omega-3-fatty acids; glucosamine; nucleic acids, oligonucleotides, antisense pharmaceuticals; enzymes; cytokines; cytokine analogues; cytokine agonists; cytokine antagonists; immunoglobulins; antibodies; antibody pharmaceuticals; gene therapies; lipoproteins; erythropoietin; vaccines; small and large molecule therapeutic agents for the treatment, or prevention of human and animal diseases such as allergy/asthma, arthritis, cancer, diabetes, growth impairment, cardiovascular diseases, inflammation, immunological disorders, baldness, pain, opthalmological diseases, epilepsy, gynecological disorders, CNS diseases, viral infections, bacterial infections, parasitic infections, GI diseases, obesity, and haemological diseases.
- Some specific non-limiting examples of suitable biologically active compounds include:
- including amino-ester and amino-amide anaesthetics such as benzocaine, chloroprocaine, ***e, reserpine, guanethidine, cyclomethycaine, dimethocaine/larocaine, propoxycaine, procaine/novocaine, proparacaine, tetracaine/amethocaine; articaine, bupivacaine, carticaine, cinchocaine/dibucaine, etidocaine, levobupivacaine, lidocaine/lignocaine, mepivacaine, piperocaine, prilocaine, ropivacaine, trimecaine, propofol, halothane, enflurane barbiturates, benzodiazepines, neostigmine and ketamine
- including carmustine, cyclophosphamide, ifosfamide, streptozotocin and mechlorethamine
- including amlodipine, aranidipine, azelnidipine, barnidipine, benidipine, cilnidipine, clevidipine, cronidipine, darodipine, dexniguldipine, efonidipine, elnadipine, elgodipine, felodipine, flordipine, furnidipine, iganidipine, isradipine, lacidipine, lemildipine, lercanidipine, manidipine, mesuldipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, olradipine, oxodipine, palonidipine, pranidipine, sagandipine, sornidipine, teludipine, tiamdipine, trombodipine, watanidipine, verapamil, gallopamil, benzothiazepine, diltiazem, mibefradil, bepridil, fluspirilene and fendiline
- including amiodarone, disopyramide, flecainide acetate, quinidine sulphate, nitroglycerine, ranolazine, amiodarone, isosorbide and alteplase
- including amoxicillin, ampicillin, azithromycin, benethamine penicillin, bleomycin, benzoyl peroxide, cinoxacin, chloramphenicol, daunorubicin, plicamycin, fluoroquinolones, ciprofloxacin, clarithromycin, clindamycin, clindesse, clofazimine, chlorohexidine gluconate, cloxacillin, demeclocycline, doxycycline, erythromycin, ethionamide, imipenem, indomethacin, lymocycline, minocycline, nalidixic acid, nitrofurantoin, penicillin, rifampicin, spiramycin, sodium sulfacetamide, sulphabenzamide, sulphadoxine, sulphamerazine, sulphacetamide, sulphadiazine, sulphafurazole, sulphamethoxazole, sulphapyridine, tetracycline, cephalexin, cefdinir, triclosan, ofloxacin, vancocin, glyburide, mupirocin, cefprozil, cefuroxime axetil, norfloxacin, isoniazid, lupulone, D-penicillamine, levofloxacin, gatifoxacin, and trimethoprim
- including doxorubicin, 6-thioguanine, paclitaxel, docetaxel, camptothecin, megestrol acetate, navelbine, cytarabine, fludarabine, 6-mercaptopurine, 5-fluorouracil, teniposide, vinblastine, vincristine, cisplatin, colchicine, carboplatin, procarbazine and etopside
- including alprazolam, amoxapine, bentazepam, bromazepam, clorazipine, clobazam, clotiazepam, diazepam, lorazepam, flunitrazepam, flurazepam, lormetazepam, medazepam, nitrazepam, oxazepam, temazepam, maprotiline, mianserin, nortriptyline, risperidone, sertraline, trazodone, baloperidol, trimipramine maleate fluoxetine, ondansetron, midazolam, chlorpromazine, haloperidol, triazolam, clozapine, fluopromazine, fluphenazine decanoate, fluanisone, perphenazine, pimozide, prochlorperazine, sulpiride, thioridazine, paroxitine, citalopram, bupropion, phenelzine, olanzapine, divalproex sodium and venlafaxine
- including azothiopine, amitriptyline, famotidine, promethazine, paroxatine, oxcarbazapine and mertazapine
- including acetohexamide, chlorpropamide, glibenclaraide, gliclazide, glipizide, metformin, tolazamide, glyburide, glimepiride and tolbutamide
- including beclamide, carbamazepine, gapapentin, tiagabine, vigabatrin, topiramate, clonazepam, ethotoin, methoin, methsuximide, methylphenobarbitone, oxcarbazepine, paramethadione, phenacemide, phenobarbitone, phenyloin, phensuximide, primidone, sulthiamine, phenytoin sodium, nirofurantoin monohydrate, gabapentin, lamotrigine, zonisamide, ethosuximide and valproic acid
- including zolpidem tartrate, amylobarbitone, barbitone, butobarbitone, pentobarbitone, brotizolam, carbromal, chlordiazepoxide, chlormethiazole, ethinamate, meprobamate, methaqualome, cyclobenzaprene, cyclobenzaprine, tizanidine, baclofen, butalbital, zopiclone, atracurium, tubocurarine and Phenobarbital
- including amphotericin, butoconazole nitrate, clotrimazole, econazole nitrate, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole, miconazole, natamycin, nystatin, sulconazole nitrate, terconazole, tioconazole and undecenoic acid; benznidazole, clioquinol, decoquinate, diiodohydroxyquinoline, diloxanide furoate, dinitolmide, furzolidone, metronidazole, nimorazole, nitrofurazone, ornidazole, terbinafine, clotrimazole, chloroquine, mefloquine, itraconazole, pyrimethamine, praziquantel, quinacrine, mebendazole and tinidazole
- including candesartan, hydralazine, clonidine, triamterene, felodipine, gemfibrozil, fenofibrate, nifedical, prazosin, mecamylamine, doxazosin, dobutamine and cilexetil
- including dihydroergotamine mesylate, ergotamine tartrate, methysergide maleate, pizotifen maleate and sumatriptan succinate
- including atropine, benzhexol, biperiden, ethopropazine, hyoscyamine, mepenzolate bromide, oxybutynin, oxyphencylcimine and tropicamide
- including aminoglutethimide, amsacrine, azathioprine, busulphan, chlorambucil, cyclosporin, dacarbazine, estramustine, etoposide, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitozantrone, procarbazine, tamoxifen citrate, testolactone, tacrolimus, mercaptopurine and sirolimus
- including bromocriptine mesylate, levodopa, tolcapone, ropinirole, bromocriptine, hypoglycaemic agents such as sulfonylureas, biguanides, α-glucosidase inhibitors, thaiazolidinediones, cabergoline, carbidopa and lysuride maleate
- including carbimazole and propylthiouracil
- including amantadine, retinovir, cidofovir, acyclovir, famciclovir, ribavirin, amprenavir, indinavirm, rimantadine and efavirenz, penciclovir, ganciclovir, vidarabine, abacavir, adefovir, apmrenavir, delavirdine, didanosine, stavudine, zalcitabine, zidovudine, enfuvirtide and interferon
- including amrinone, milrinone, digitoxin, digoxin, enoximone, lanatoside C and medigoxin
- including fenofibrate, clofibrate, probucol, ezetimibe and torcetrapib
- including meoxicam, triamcinolone, cromolyn, nedocromil, hydroxychloroquine, montelukast, zileuton, zafirlukast and meloxicam
- including fexofenadine, chloral hydrate, hydroxyzine, promethazine, cetirazine, cimetidine, clyclizine, meclizine, dimenhydrinate, loratadine, nizatadine and promethazine
- including omeprazole, lansoprazole, pantoprazole and ranitidine
- including hydrochlorothiazide, amiloride, acetazolamide, furosemide and torsemide
- including natural opiates which are alkaloids contained in the resin of the opium poppy such as morphine, codeine and thebaine; semi-synthetic opioids created from natural opiates such as hydromorphone, hydrocodone, oxycodone, oxymorphone, desomorphine, diacetylmorphine (heroin), nicomorphine, dipropanoylmorphine, benzylmorphine and ethylmorphine; fully synthetic opioids such as fentanyl, pethidine, methadone, tramadol and dextropropoxyphene; and, endogenous opioid peptides, produced naturally in the body, such as endorphins, enkephalins, dynorphins, and endomorphins; opioid analgesics including opioid receptor agonists, opioid receptor partial agonists, opioid antagonist or opioid receptor mixed agonist-antagonists; opioid receptor agonists including morphine, depomorphine, etorphine, heroin, hydromorphone, oxymorphone, levorphanol, methadone, levomethadyl, meperidine, fentanyl, sufentanyl, alfentanil, codeine, hydrocodone, oxycodone, and mixtures of the foregoing; opioid receptor antagonists including naloxone and naltrexone; opioid receptor mixed agonist-antagonist which has mixed opioid agonist/antagonist activities, or one that exhibits only partial agonist activity, including buprenorphine, nalbuphine, butorphanol, pentazocine, and mixtures of such compounds; opioids which exhibit partial agonist activity, including ethylketocyclazocine; opium alkaloids including phenanthrenes which are naturally occurring in opium such as codeine, morphine, thebaine and oripavine (the active metabolite of thebaine); synthetic derivatives such as diacetylmorphine (heroin), dihydrocodeine, hydrocodone, hydromorphone, nicomorphine, desmorphine, ethylmorphine, dipropanoylmorphine, oxycodone and oxymorphone; synthetic opioids including anilidopiperidines such as fentanyl, alphamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanyl and ohmefentanyl, Phenylpiperidines such as pethidine (meperidine), ketobemidone, MPPP, allylprodine, prodine and PEPAP; diphenylpropylamine derivatives such as propoxyphene, dextropropoxyphene, dextromoramide, bezitramide, piritramide, methadone, dipipanone, levomethadyl acetate (LAAM), difenoxin, diphenoxylate and loperamide; benzomorphan derivatives such as dezocine, pentazocine and phenazocine; oripavine derivatives such as buprenorphine, dihydroetorphine and etorphine; morphinan derivatives such as butorphanol, nalbuphine, levorphanol and levomethorphan, and others such as lefetamine, meptazinol, tilidine, tramadol and tapentadol; opioid receptor antagonists including nalmefene, naloxone and naltrexone
- including arylalkanoic acid sub-group of class which includes diclofenac, aceclofenac, acemetacin, alclofenac, bromfenac, etodolac, indometacin, indometacin farnesil, nabumetone, oxametacin, proglumetacin, sulindac and tolmetin; 2-arylpropionic acid (profens) sub-group of class which includes alminoprofen, benoxaprofen, carprofen, dexibuprofen, dexketoprofen, fenbufen, fenoprofen, flunoxaprofen, flurbiprofen, ibuprofen, ibuproxam, indoprofen, ketoprofen, ketorolac, loxoprofen, miroprofen, naproxen, oxaprozin, pirprofen, suprofen, tarenflurbil and tiaprofenic acid; and N-arylanthranilic acid (fenamic acid) sub-group of class which includes flufenamic acid, meclofenamic acid, mefenamic acid and tolfenamic acid; tromethamine, celecoxib, nepafenac, aspirin, rofecoxib, naproxen, sulindac, piroxicam, pheylbutazone, tolmetin, indomethacin, acetominophen (paracetamol), tramadol and propoxyphene
- including first generation retinoids such as retinol, retinal, tretinoin (retinoic acid, Retin-A), isotretinoin and alitretinoin; second generation retinoids such as etretinate and its metabolite acitretin; third generation retinoids such as tazarotene, bexarotene and adapalene
- including adrenocorticotrophic hormone (ACTH), antidiruetic hormone (vasopressin), atrial-nartreuretic factor (ANF), atrial-nartreuretic peptide (ANP), beclomethasone, cortisone, scopolamine, dopamine, epinephrine, catecholamines, cholecystokinin, clomiphene citrate, danazol, dexamethasone, diethylstilbestrol (DES), ethinyl estradiol, fludrocortison, finasteride, follicle stimulating hormone, gastrin, hydroxyprogesterone, growth hormone, insulin, leptin, luteinizing hormone, medroxyprogesterone acetate, mestranol, quinestrol, methyltestosterone, nandrolone, norethindrone, norethisterone, norgestrel, estradiol, conjugated oestrogens, oxandrolone, oxytocin, prednisone, progesterone, prolactin, protogalndins, somatostatin, stanozolol, stibestrol, thyroxine, prednisolone phosphate, triamcinolone, mifepristone acetonide, budesonide, levothyroxine, testosterone, testosterone cypionate, fluoxymesterone, flutamide, mometasone furoate, cyproterone, fluromethalone, goserelin, leuprolide, calcitonin, halobetasol, hydrocortisol and tibolone
- including atorvastatin, fluvastatin, lovastatin, nystatin, rosuvastatin, pravastatin, orlistat and simvastatin
- including amphetamine, phentermine, tyramine, ephedrine, metaraminol, phenylephrine, dexamphetamine, dexfenfluramine, fenfluramine, nicotine, caffeine and mazindol
- including desmopressin
- including carvedilol, terazosin, phentolamine and menthol
- including levetiracetam, levitiracetam and donepezil
- including benzapril, enalapril, ramipril, fosinopril sodium, lisinopril, minoxidil, isosorbide, rampril and quinapril
- including atenolol, timolol, pindolol, propanolol hydrochloride, bisoprolol, esmolol, metoprolol succinate, metoprolol and metoprolol tartrate
- including losartan
- including abciximab, clopidrogel, tirofiban and aspirin
- including tramadol, tramadol hydrochloride, allopurinol, calcitriol, cilostazol, soltalol, urasodiol bromperidol, droperidol, flupenthixol decanoate, albuterol, albuterol sulphate, carisoprodol, chlobetasol, ropinirol, labetalol, and methocarbamol
- including amioderone, fluticasone, spironolactone, prednisone, triazodone, desoximetasone, methyl prednisdone, benzonatate nabumetone and buspirone
- including metoclopramide
- including dorzolamide, brimonidine, olopatadine, cyclopentolate, pilocarpine and echothiophate
- including warfarin, enoxaparin and lepirudin
- including probenecid and sulfinpyrazone
- including ipratropium
- including raloxifene, pamidronate and risedronate
- including acetyl hexapeptide-3, acetyl hexapeptide-8, acetyl octapeptide and 1-carnosine
- including vaccines comprising toxoids (inactivated toxic compounds); proteins, protein subunits and polypeptides; polynucleotides such as DNA and RNA; conjugates; adjuvants such as saponins, virosomes, inorganic and organic adjuvants, for example zostavax
- including coenzyme Q10 (or ubiquinone), ubiquinol or resveratrol; a carotenoid such as α, β, or γ-carotene, lycopene, lutein, zeaxanthin and astaxanthin; a phytonutrient, such as lycopene, lutein and seaxanthin; an unsaturated fatty acid such as linoleic acid, conjugated linoleic acid, linolenic acid, omega-3 fatty acids including but not limited to docosahexaenoic acid (DHA) and eicosapentaeonic acid (EPA) and their glycerol-esters; fat-soluble vitamins including vitamin D (D2, D3 and their derivatives), vitamin E (α, β, γ, δ-tocopherols, or α, β, γ, δ-tocotrienols), vitamin A (retinol, retinal, retinoic acid and derivatives), vitamin K (K1, K2, K3 and their derivatives) capric/caprylic triglycerides, folic acid, iron, niacin, glyceryl linoleate, omega 6 fatty acids, vitamin F, selenium, cyanocobalamin, aloe vera, beta glucan, bisabolol, camellia thea (green tea) extract, capric/caprylic triglycerides, centella asiatica (gotu cola) extract, cetearyl olivate, chlorophyll, citrus sinensis (orange) oil, cocoyl proline, dicapryl ether, disodium lauriminodipropionate tocopheryl phosphates (vitamin E phosphates), glycerin, glyceryl oleate, glycyrrhiza glabra (licorice) root extract, hamamelis virgiana (witch hazel) extract, lactic acid, lecithin, lutein, macadamia integrifolia (macadamia) seed oil, matricaria chamomilla (chamomile) extract, oenothera biennis (evening primrose) oil, olea europaea (olive) leaf extract, rice bran oil, persea gratissima (avocado) oil, polygonum multiflorum extract, pomegranate sterols, resveratrol, rosa eglanteria (rose hip) oil, santalum spicatum (sandalwood) oil, titanium dioxide, folic acid, glycerin, glyceryl linoleate (omega 6 fatty acids vitamin F), vitamin A palmitate, vitis vinifera (grapeseed) oil, halobetasol, adenosine, adenosine triphosphate, alpha hydroxy acid, allantoin, hyaluronic acid and derivatives, isolutrol, tranexamic acid, glycolic acid, arginine, ascorbyl glucosamine, ascorbyl palmitate, salicylic acid, carnosic acid, alpha lipoic acid, gamma linolenic acid (GLA), panthenol, retinyl propionate, retinyl pamitate, furfuryladenine, retinaldehyde, copper peptides, idebenone, dimethylaminoethanol (DMAE), niacinamide, beta-glucan, palmitoyl pentapeptide-4, palmitoyl oligopeptide/tetrapetide-7, ethocyn, ceramides, phenylalanine, glucuronolactone, L-carnitine, hydroxylapetite, palmitoyl tripetide-3, forskolin, zinc oxide, α-bisabolol, eugenol, silybin, soy isoflavones, aucubin, catalpol, pseudoguaianolide from Arnica chamissonis, rosmarinic acid, rosmanol, salicylates for example salicin, saligenin and salicyclic acid, taxasterol, α-lactucerol, isolactucerol, taraxacoside, ceremides, arbutin, gingerols, shagaols, hypercin, elastin, collagen and peptides thereof.
- Particularly preferred biologically active compounds include alprazolam, donepazil, rispiredone, lorazepam, nicotine, lidocaine, diclofenac, felodipine, insulin, ketoralac, prilocaine, halobetasol, hydrocortisol, opioids such as oxycodone or dihydrohydroxycodeinone (oxycodone base).
- It is to be understood that pharmaceutically, nutraceutically or cosmeceutically acceptable derivatives of biologically active compounds are included within the scope of the present invention.
- The term “pharmaceutically, nutraceutically or cosmeceutically acceptable derivatives” includes, but is not limited to, pharmaceutically, nutraceutically or cosmeceutically acceptable salts, esters, salts of such esters, ethers, or any other derivative including prodrugs and metabolites, which upon administration to a subject (e.g. patient, human or animal) in need is capable of providing, directly or indirectly, a biologically active compound as otherwise described herein.
- As used herein, the term “pharmaceutically, nutraceutically or cosmeceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically, nutraceutically or cosmeceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically, nutraceutically or cosmeceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19, 1977. Examples of pharmaceutically, nutraceutically or cosmeceutically acceptable nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hernisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate, and aryl sulfonate.
- The term “pharmaceutically, nutraceutically or cosmeceutically acceptable ester” refers to esters which are hydrolysed in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically, nutraceutically or cosmeceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
- The term “pharmaceutically, nutraceutically or cosmeceutically acceptable prodrugs” as used herein refers to those prodrugs of the biologically active compounds which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term “prodrug” refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.
- The present invention is further not limited solely to the administration of one biologically active compound: more than one biologically active compound or other therapeutic compounds may be incorporated into the composition, or matrix layer.
- The biologically active compound may be present in a therapeutically effective amount, that is, an amount necessary to achieve a desired therapeutic effect. Typically, the biologically active compound will be present in an amount within the range of about 0.1% w/w to about 30% w/w, within the range of about 0.1% w/w to about 20% w/w, within the range of about 0.1% w/w to about 10% w/w, of the total concentration of the composition, or matrix layer. In one embodiment, the matrix layer will have a biologically active compound concentration within the range of about 3.0% w/w to about 15.0% w/w of the total concentration of the composition, or matrix layer.
- The ratio of biologically active compound:TP (% w/w) may be within the range of about 5:5 to about 5:0.5, with the most preferred value preferably being about 5:1. The polymer carrier:[biologically active compound and TP] may be within the range of about 1:1 to about 3:1, with preferred values preferably being within the range of about 7:6 to about 7:3.
- The composition, or matrix layer, may form part of a transdermal delivery matrix patch. The transdermal delivery patch may be prepared by a variety of techniques.
- One technique involves combining the polymer carrier and any inert carrier components such as an anti-tacking agent and/or plasticizer with a suitable solvent (e.g. 50% water, 50% ethanol). This is combined with a dispersion comprising the biologically active compound and the mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound, and is stirred until complete homogenisation is achieved. In one embodiment, the composition may then be placed in a suitable mould and dried. In a preferred method, the composition may be dried by heating up to about 90° C., preferably for 0.5 to 24 hours. However, formulating and/or drying may be conducted at a temperature within the range of about 30° C. to about 90° C. It has been found that formulating and/or drying at a temperature of about 75° C. results in better delivery of the biologically active compound. In an alternate embodiment, the composition may be cast on a surface (e.g. a roller) and then dried under heat.
- The composition comprising a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound and a polymer carrier is suitable for use as a matrix layer. The matrix layer may be a solid or semi-solid layer.
- The transdermal delivery patch usually would also comprise a backing layer. The backing layer acts as a support or substrate for the composition, or matrix layer. When preparing a transdermal delivery patch using a mould, the backing layer would be placed in the mould before addition of the composition, or matrix layer.
- Accordingly, the composition, or matrix layer, essentially has two surfaces: a first surface and a second surface opposite the first surface, where the first surface is in contact with the backing layer and the second surface being adapted to be in diffusional contact with the skin of a subject. The subject may be a human or animal.
- Preferably, the backing layer is occlusive or impermeable to protect the composition, or matrix layer, from the outer environment. However, a non-occlusive backing layer could also be used, so long as the packaging of the transdermal delivery patch is fully occlusive to prevent degradation of the composition, or matrix layer. An occlusive backing layer is preferred.
- The backing layer may be of any thickness, however in the art, backing layers typically have a thickness of about 0.0005 inches to about 0.01 inches.
- The transdermal delivery patch may further comprise a liner which is a removable protective or impermeable layer, usually but not necessarily rendered “non-stick” so as not to stick to the composition, or matrix layer. The liner, which may also be referred to as the release liner, protects the transdermal delivery patch during storage. During use, the release liner is to be removed.
- The liner may be made from the same material as the backing layer, however it may also be a metal foil, Mylar (registered trademark), polyethylene terephthalate, siliconized polyester, fumed silica in silicone rubber, polytretrafluoroethylene, cellophane, siliconized paper, aluminized paper, polyvinyl chloride film, composite foils or films containing polyester such as polyester terephthalate, polyester or aluminized polyester, polytetrafluoroethylene, polyether block amide copolymers, polyethylene methyl methacrylate block copolymers, polyurethanes, polyvinylidene chloride, nylon, silicone elastomers, rubber-based polyisobutylene, styrene, styrene-butadiene, and styrene-isoprene copolymers, polyethylene, and polypropylene.
- The release liner may be of any thickness, however in the art, release liners typically have a thickness of about 0.01 mm to about 2 mm.
- The transdermal delivery patch may also comprise an adhesive layer. The adhesive layer may be an additional layer to the composition, or matrix layer, or may be included on the outer margin of the backing layer where the backing layer extends beyond the edges of the composition, or matrix layer. Polymeric adhesives useful for transdermal patches include polyacrylate polymers, rubber-based adhesives and polysiloxane adhesives. These types of materials, as well as others, are described by Van Norstrand (The Handbook of Pressure Sensitive Adhesive Technology Second Edition 1989), which is hereby incorporated by reference. Examples of commercially available adhesives include, but are not limited to, polyacrylate adhesives sold under the trademarks DUROTAK (registered trademark) by National Starch and Chemical Corporation, Bridgewater, N.J., as well as GELVA-MULTIPOLYMER SOLUTION (registered trademark) by Cytek Surface Specialties, Smyrna, Ga.
- It has surprisingly been found that biologically active compounds can be effectively administered using a transdermal delivery patch comprising a composition, or matrix layer, which comprises a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound and a polymer carrier.
- Transdermal delivery options for include, for example, topical creams and gels, and skin patches.
- Creams and gels may present difficulties with compliance and dosage control, and may be considered messy or unpleasant by patients.
- There are different forms of skin patches, including “reservoir” patches and “matrix” patches. Patches may also be single- or multi-layered. A “reservoir” patch essentially has a liquid or gel compartment containing the drug solution or suspension separated by a membrane and a layer of adhesive. In a “matrix” patch, the drug dispersion is present in a semi-solid or solid layer, which may or may not also comprise the adhesive material.
- Reservoir patches overcome some of the dosage difficulties with topical creams and gels, however the delivery may be uneven or inconsistent, and there is some risk of perforation of the reservoir. An additional issue relates to delivery of prescribed drugs which may be addictive and subject to abuse. Gels, creams and reservoir patches provide limited barriers to extraction of the drug substance, whereas incorporation of the drug substance within a composition, or matrix layer, represents a significant, if not almost impossible barrier to extraction of the drug substance.
- Delivery of an active orally or by injection typically results in a delivery profile which is non-linear. Transdermal delivery provides a non-invasive way of potentially achieving sustained steady state delivery.
- Without wishing to be bound by theory, the presence of a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound is considered to enhance the skin permeation of the biologically active compound. It has also been found that the components of the composition, or matrix layer, do not formulate well together without the presence of a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound. It has also been found that the presence of a phosphate compound of tocopherol will act to reduce skin irritation caused by many the biologically active compounds.
- The examples will be described with reference to the accompanying figures in which:
-
FIG. 1 is a schematic diagram of a transdermal delivery patch of one embodiment of the present invention; -
FIG. 2 is a graph comparing the delivery of oxycodone using a transdermal delivery patches of the present invention prepared with different drying regimes; -
FIG. 3 is a graph comparing the delivery of oxycodone using transdermal delivery patches of the present invention prepared with and without a glue layer; -
FIG. 4 is a graph comparing the delivery of oxycodone using transdermal delivery patches of the present invention prepared with and without an occlusive backing layer; -
FIG. 5 is a graph showing the results of pharmacokinetic testing conducted after application of transdermal delivery patches of the present invention; -
FIG. 6 is a graph showing the results of pharmacodynamic testing conducted after application of transdermal delivery patches of the present invention; -
FIG. 7 is a graph comparing the delivery of oxycodone using transdermal delivery patches of the present invention comprising different plasticisers; -
FIG. 8 is a graph comparing the delivery of oxycodone using transdermal delivery patches of the present invention comprising different plasticisers and polymer carriers; -
FIG. 9 is a graph showing the average change in blood glucose after application of transdermal delivery patches of the present invention to each of the animals;FIG. 10 is a graph showing the area under the curve of the graph ofFIG. 9 ; -
FIGS. 11 and 12 are graphs comparing the deposition in skin of two diclofenac transdermal delivery patches; and -
FIG. 13 is a graph comparing the permeation of two lidocaine transdermal delivery patches. - Various embodiments/aspects of the present invention will now be described with reference to the following non-limiting examples.
-
-
Final composition, or matrix layer Percentage by Components weight, after drying A combination of mono-(tocopheryl) 1.1% w/w phosphate and di-(tocopheryl) phosphate in a ratio of 6:4 Oxycodone 5.5% w/w Eudragit E100 (polymethyl methacrylate) 60.6% w/w Dibutyl sebacate 27.3% w/w Succinic acid 5.5% w/w - The components were dissolved in a solvent solution (acetone:isopropanol:ethyl alcohol 60:6.6:33.5 by % weight).
- The resulting solution was then poured into individual casts (containing suitable backing layers) at room temperature and the solvent was allowed to evaporate at 75° C. for 1.5 hours.
- All composition, or matrix layer, components could be combined at a suitable temperature to produce a homogeneous molten mass. The molten mass can then be cast on a cold surface (for example, a rotating mill with a suitable backing layer, or sheet, thereon) and allowed to solidify. Individual transdermal delivery patches of varying sizes may then be cut.
- In both methods, the composition, or matrix layer, would be relatively thin; however, the thickness of the composition, or matrix layer, can be varied depending on the desired properties of the transdermal delivery patch.
FIG. 1 shows an example of a transdermal delivery patch of one embodiment of the present invention. - Transdermal delivery patches were constructed by dissolving 20% w/w solid mixture of Eudragit E100 granules, dibutyl sebacate, succinic acid (the components other than TPM and oxycodone in the composition, or matrix layer, may collectively be referred to as the “polymer carrier”); a combination of mono-(tocopheryl) phosphate and di-(tocopheryl) phosphate in a ratio of 6:4 (TPM); and oxycodone base in 60:6.6:33.4 acetone/isopropyl alcohol/ethyl alcohol. The mixture was then transferred into 6 cm2 circular aluminium cast-lined on the underside with polyester backing (1.66 mil, 3M Scotchpak™, 3M, MN) and the solvent evaporated in an oven at either 45° C. overnight or 75° C. for 1.5 hours. Where glue was used, the glue was DuroTak adhesive and in this example succinic acid was omitted from the formulation.
-
TABLE Composition, excipient ratios and manufacture conditions of transdermal delivery patches Ratio Oxycodone Vol. stock Succinic Patch (PC:O:TPM)* (mg) (ml) Dry temp./ time acid Glue 1 10:5:1 10 2 45° C. overnight Yes No 2 14:5:1 10 2 45° C./overnight Yes No 3 14:5:1 5 1 45° C./overnight Yes No 4 14:5:1 5 1 75° C./1.5 h Yes No 5 14:10:2 5 0.5 75° C./1.5 h No Yes *Refers to ratio of polymer carrier:oxycodone:TPM - Oxycodone transdermal delivery patches were made according to Example 1 (small scale), testing the variable of the two different heating regimes. The transdermal delivery patches were adhered to full thickness human skin applied to a Franz cell with PBS as the receiver solution. Time points were taken at 18, 22, 24, 42, 44, 68 and 75 hours and the receiver solution was tested by HPLC to determine the concentration of oxycodone which had passed through the skin.
-
TABLE Parameters in the patches tested Ratio Oxycodone Vol. stock Succinic Patch (PC:O:TPM)* (mg) (ml) Dry temp./time acid Glue A 14:5:1 10 2 45° C./overnight Yes No B 14:5:1 10 2 75° C./1.5 h Yes No *Refers to ratio of polymer carrier:oxycodone:TPM - The results outline in
FIG. 2 show that the transdermal delivery patch manufactured using the higher (accelerated) drying temperature has increased transdermal delivery properties compared with the transdermal delivery patch manufactured with drying at a lower temperature. - Transdermal delivery patches were manufactured and the receiver solution tested as in Example 3, with testing time points of 0.5, 1, 3, 4 and 20 hours.
-
TABLE Parameters in the patches tested Ratio Oxycodone Vol. stock Succinic Patch (PC:O:TPM)* (mg) (ml) Dry temp./time acid Glue C 14:5:1 10 2 75° C./1.5 h Yes No D 14:5:1 10 2 75° C./1.5 h No Yes *Refers to ratio of polymer carrier:oxycodone:TPM - The results of this comparison outlined in
FIG. 3 clearly demonstrate that using a transdermal delivery patch which includes an adhesive layer results in reduced transdermal penetration of the oxycodone compared with the transdermal delivery patches formulated to be self-adhesive. - The transdermal delivery patches were manufactured and the receiver solution tested as in Examples 3 and 4, at
time points -
TABLE Parameters in the patches tested Ratio Oxycodone Vol. stock Occlusive Patch (PC:O:TPM)* (mg) (ml) Dry temp./time backing Glue E 14:5:1 10 2 75° C./1.5 h Yes No F 14:5:1 10 2 75° C./1.5 h No No *Refers to ratio of polymer carrier:oxycodone:TPM - The results outlined in
FIG. 4 clearly show that penetration of the oxycodone transdermally is far superior when an occlusive backing layer is used with the patch compared with a patch without the adhesive backing layer. - This example compares plasma PK parameters using Patch Nos. 1, 2, 4 and 5 from Example 2.
- Transdermal delivery patches were cut from the polyester backing and adhered to the shaved and washed back of a 10-12 week old male Sprague-Dawley rat with a 6×7 cm Tegaderm HP™ (3M, MN) adhesive dressing either with the backing layer in place or removed (see Table below). Tegaderm serves to hold the occlusive backing layer in place, or if the backing layer is absent, holds the transdermal delivery patch itself in place.
- The day after the transdermal delivery patches were adhered to the shaved section, blood samples removed from the tail tip following ˜1 mm tip amputation at specified times.
- The PK parameters quantified were:
- Cmax: the maximal observed plasma oxycodone concentration.
- AUC0-4: The area under the curve between 0 and 4 hours (the duration of the experiment was 4 hours) and is a measure of the total amount of drug delivered.
- The results in
FIG. 5 and Table below demonstrate that the transdermal delivery patches of the present invention in various formulations are able to effectively deliver the oxycodone to the rats as demonstrated by the pharmacokinetic data. -
TABLE Estimated pharmacokinetic parameters of rats administered transdermal delivery patches Oxycodone Cmax AUC0-4 Patch dose (mg/kg) Occlusive n (ng/mL) (ng · mL/min) 1 41.8 ± 0.4 No 17 93 ± 16 13681 ± 2367 2 45.0 ± 2.1 Yes 9 92 ± 27 11959 ± 2910 4 21.7 ± 0.1 Yes 5 144 ± 33 21637 ± 5189 5 18.1 ± 0.3 Yes 5 74 ± 29 11161 ± 4636 ‘n’ = no. of animals - Rats were prepared and dosed similar to Example 6 using Patch Nos. 1, 3 and 5 from Example 2.
- The day after the transdermal delivery patches were adhered to the shaved section, antinociception of the hind-paw was assessed with a plantar analgesiometer with the IR source calibrated to 190 Mu/cm2.
- The following PD parameters were assessed:
- Maximum: The maximum time it took for the rat to remove its paw in response to the heat stimulus. The higher the number, the longer it took for the rat to respond and the deeper the oxycodone induced analgesia.
- AUC: This is a measure of the total analgesia over the observation period as measured by the area under the curve between 0 and 4 hour, and is useful for comparing the response to different treatments.
- The baseline response time is indicated in
FIG. 6 at t=(−0.5 h) and t=0. - The results outlined in the Table below and
FIG. 6 demonstrate that analgesia was effectively administered to the rats using a variety of compositions of the present invention. -
TABLE Pharmacodynamic parameters from rats administered different transdermal delivery patches Oxycodone Patch dose (mg/kg) n Max (sec.) AUC0-4 (sec/h) 1 41.0 ± 0.8 5 20.7 ± 3.5 57.6 ± 9.1 3 21.8 ± 0.6 5 22.3 ± 3.3 76.8 ± 13.1 5 21.6 ± 0.5 4 20.5 ± 2.3 64.0 ± 6.4 ‘n’ = no. of animals - The following formulations were prepared as outlined in Example 2.
Formulation 1 was cast onto a die andFormulation 2 was cast onto a plate. The percentages below reflect the composition when the patch is dry. -
Formulation 1 (1% T80, dbs) % w/ w Eudragit 100 60.59 DBS 26.28 Succinic acid 5.46 Oxycodone 5.56 Tocopheryl phosphate 0.67 Di-tocopheryl phosphate 0.44 Tween 801.00 100.00 -
Formulation 2 (3% ML, 25% T) % w/ w Eudragit 100 60.59 Transcutol 24.28 Succinic acid 5.46 Oxycodone 5.56 Tocopheryl phosphate 0.67 Di-tocopheryl phosphate 0.44 Methyl laurate 3.00 100.00 - The transdermal delivery patches were adhered to full thickness human skin applied to a Franz cell with PBS as the receiver solution. Time points were taken at 1, 2, and 4 hours and the receiver solution was tested by HPLC to determine the concentration of oxycodone which had passed through the skin.
- The results are outlined in
FIG. 7 and demonstrate that delivery of oxycodone can be achieved using alternate plasticisers. - The following formulations were prepared as in Example 1, however with the composition was cast onto a flat surface or plate instead of a die.
-
20% tran, 20% tran, 3% ML, 1% Lau, 20% tran, 1 % Span 1 % Span 1 % Span 3 % ML 1 % Span 20% w/ w transcutol 20% w/ w transcutol 20% w/ w transcutol 3% w/ w Methyl laurate 1% w/ w Span 803% w/ w Methyl laurate 1% Lauric acid 1% w/ w Span 80DuroTak to 100% w/w DuroTak to 100% w/ w 1% w/ w Span 801% w/ w Span 80DuroTak to 100% w/w 5.5% w/w Oxycodone 5.5% w/w Oxycodone DuroTak to 100% w/w DuroTak to 100% w/w 5.5% w/w Oxycodone 1.1% w/w TPM 1.1% w/w TPM 5.5% w/w Oxycodone 5.5% w/w Oxycodone 1.1% w/w TPM 1.1% w/w TPM 1.1% w/w TPM - The transdermal delivery patches were adhered to full thickness human skin applied to a Franz cell with PBS as the receiver solution. Time points were taken at 1, 2, and 4 hours and the receiver solution was tested by HPLC to determine the concentration of oxycodone which had passed through the skin.
- The results are outlined in
FIG. 8 and demonstrate that oxycodone can be delivered transdermally using an alternate polymer carrier. - Four transdermal delivery patches of the present invention were tested against a positive control gel.
- The table below sets out the composition of the composition, or matrix layer, in each of the four transdermal delivery patches. The polyvinylpyrrolidone was found to provide the composition, or matrix layer, with sufficient “tackiness” to avoid the need to include any inert carrier components. The dry weight of each transdermal delivery patch was 60 mg.
-
Patch TPM Polyvinylpyrrolidone Insulin 1 1.2 mg (2% w/w) 54.8 mg (91.33% w/w) 4 mg (6.67% w/w) 2 0.6 mg (1% w/w) 55.4 mg (92.33% w/w) 4 mg (6.67% w/w) 3 0.6 mg (1% w/w) 56.4 mg (94.0% w/w) 3 mg (5% w/w) 4 1.2 mg (2% w/w) 50.8 mg (84.6% w/w) 8 mg (13.33% w/w) - The components of the composition, or matrix layer, were dissolved in a solvent solution (50% water, 50% ethanol). The resulting solution was then poured into individual casts (containing suitable backing layers) at room temperature and the solvent was allowed to evaporate at 75° C. for 1.5 hours.
- 300 mg of gel was used as the positive control, which comprised 2.25 mg/ml insulin, 2% TPM (2:1), 30% ethanol, 1% carpobol 934 in water adjusted to pH=4.7.
- The study was a cross-over design to test the effect of transdermal delivery patches of the present invention compared to the gel. In this design, each animal received four of the five treatments across the course of the study. The animals were male and 10-12 weeks of age. Each treatment group was 11 animals. All animals were >300 g in weight, and had circulating glucose concentrations of >10 mmol/L in the fasted state (mean fasted glucose concentration was 21.37±0.85 mmol/L). The key endpoint of the study was blood glucose levels during a 5-hour insulin tolerance test, conducted as described below.
- Diabetes was induced by the administration of a single intraperitoneal injection of streptozotocin (STZ) 50 mg/kg (Sigma Chemicals) dissolved in sodium citrate buffer (0.1 mol/L, pH 4.5) immediately before use. Rats were considered diabetic and included in the study if their blood glucose was greater than 16 mmol/L 24 hours after the STZ injection. In all groups blood glucose measurements were made by obtaining a spot sample from tail tipping. Animals were left for 5 days following STZ administration prior to testing.
- 24 hours before the application of the gel and transdermal delivery patches the animals were anaesthetised and ˜30 cm2 of fur was shaved from the back, avoiding any damage to the skin that could enhance absorption of the formulations. The gel was applied at a dose of 12 mg/cm2 across the shaved area. The transdermal delivery patches were adhered to the shaved area and protected with the application of a tegaderm dressing. The insulin tolerance tests were performed 24 hours after removing the fur. Following each treatment, the animals were allowed to recover for 3 days before the next treatment.
- Animals were fasted for 2 hours prior to the application of insulin or control formulations. Spot blood samples were taken from the tail at 0, 30, 60, 90, 120, 180, 240 and 300 minutes after the application of the gel and transdermal delivery patches. Blood glucose levels were determined at the same time points using glucose sticks (AccuChek, Roche Diagnostics).
- The gel and the transdermal delivery patches caused significant reductions in blood glucose concentrations in the diabetic rats (see
FIGS. 9 and 10 ). Blood glucose was significantly reduced (p<0.05) from startingvalues 30 min after application and remained lowered for the duration of the experiment. There was no statistically significant difference in the reduction of blood glucose between the patches and gel tested here, as demonstrated by the area under the curve (seeFIG. 10 ). The transdermal delivery patches appear efficacious for the delivery of insulin, however, a transdermal delivery patch provides the many advantages described herein over a gel or other methods of delivery. - Diclofenac diethylamine transdermal delivery patches were prepared having the following composition:
-
200 mg diclofenac diethylamine 20 mg TPM (8:2) 168 mg Eudragit 200 mg diclofenac diethylamine 168 mg Eudragit - The diclofenac diethylamine transdermal delivery patches had a surface area of 120 cm2.
- The components listed in the table above were dissolved in 30 ml isopropanol:acetone mixture (1:1) at 45° C. The mixture was then casted over a 3M scotch pack, and dried for 90 minutes at 75° C.
- Transdermal delivery patches were cut into circular discs (7 cm2) and placed over rat skin. Receptor solution was 12 ml and had an effective surface with the skin equal to about 1.76 cm2. After the duration of the experiment, skin (about 7 cm2) was removed, the surface cleaned (excess gel) and extracted with 10 ml solvent.
- The results are reflected in
FIGS. 11 and 12 . -
Diffusion Dose: 2.92 mg/1.76 cm2 Skin extraction Dose: 11.78 mg/7.06 cm2 - Lidocaine transdermal delivery patches were prepared having the following composition:
-
100 mg lidocaine base 20 mg TPM (8:2) 168 mg Eudragit 100 mg lidocaine base 168 mg Eudragit - The lidocaine transdermal delivery patches had a surface area of 120 cm2.
- The components listed in the table above were dissolved in 30 ml isopropanol:acetone mixture (1:1) at 45° C. The mixture was then casted over a 3M scotch pack, and dried for 90 minutes at 75° C.
- Transdermal delivery patches were cut into circular discs (7 cm2) and placed over rat skin. Receptor solution was 12 ml and had an effective surface with the skin equal to about 1.76 cm2. After the duration of the experiment, skin (about 7 cm2) was removed, the surface cleaned (excess gel) and extracted with 10 ml solvent.
- The results are reflected in
FIG. 13 . -
Diffusion Dose: 1.46 mg/1.76 cm2 Skin extraction Dose: 5.89 mg/7.06 cm2 - In this specification, except where the context requires otherwise, the words “comprise”, “comprises”, and “comprising” mean “include”, “includes”, and “including” respectively, i.e. when the invention is described or defined as comprising specified features, various embodiments of the same invention may also include additional features.
- Although this invention has been described by example and with reference to possible embodiment thereof, it is to be understood that modifications or improvements may be made thereto without departing from the scope of the invention.
Claims (25)
1. A matrix layer suitable for use in a transdermal delivery patch for administration of a biologically active compound, the matrix layer comprising a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound and a polymer carrier wherein the polymer carrier is present in an amount within the range of about 30% w/w to about 95% w/w of the total concentration of the matrix layer.
2. The matrix layer of claim 1 , wherein the mono-tocopheryl phosphate compound is selected from the group consisting of mono-(tocopheryl) phosphate, mono-(tocopheryl) phosphate monosodium salt, mono-(tocopheryl) phosphate disodium salt, mono-(tocopheryl) phosphate monopotassium salt and mono-(tocopheryl) phosphate dipotassium salt, and the di-tocopheryl phosphate compound is selected from the group consisting of di-(tocopheryl) phosphate, di-(tocopheryl) phosphate monosodium salt and di-(tocopheryl) phosphate monopotassium salt.
3. The matrix layer of claim 1 , wherein the ratio (% w/w) of the mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound is at least 2:1, within a range of about 4:1 to about 1:4, within a range of about 6:4 to about 8:2, about 2:1, about 6:4, or about 8:2.
4. The matrix layer of claim 1 , wherein the mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound is present in an amount within a range of about 0.01% w/w to about 10% w/w, within the range of about 0.1% w/w to about 5% w/w, within the range of about 0.1% w/w to about 3% w/w, within the range of about 0.1% w/w to about 2% w/w, within the range of about 0.1% w/w to about 1% w/w or within the range of about 0.1% w/w to about 0.5% w/w, of the total concentration of the matrix layer.
5. (canceled)
6. The matrix layer of claim 1 , wherein the polymer carrier comprises a natural or synthetic polymer, co-polymer, terpolymer, or combination thereof.
7. The matrix layer of claim 6 , wherein the natural polymers are selected from the group consisting of rubbers, elastomers, polysaccharides including cellulose, natural resins including shellac and amber; and, the synthetic polymers are selected from the group consisting of acrylates, polyacrylates, polyalkyl acrylates, polyamides, polyesters, polycarbonates, polyimides, polystyrenes, acrylonitrile butadiene styrene, polyacrylonitrile, polybutadiene, poly(butylene terephthalate), poly(ether sulphone), poly(ether)ketones, polyethylene, poly(ethylene glycol), poly(ethylene terphthalate), polypropylene, polytetratfluroethylene, styrene-acrylonitrile resin, poly(trimethylene terephthalate), polyurethanes, polyvinyl butyral, polyvinylchlorides, polyvinylidenedifluoride, povidones, poly(vinyl pyrrolidone), polychloroprene, fluoroelastomers, chloro-sulphonated rubbers, hypromellose, polyolefine elastomer, polyacrylamide, chlorinated polyethylene, polyethersulphone, nylon, liquid crystal polymers, polyethylene terephthalate (PET), polyphenylsulphone, polypthalaminepolyvinyl alcohol derivatives, poly ethylene glycols, ethylene vinyl acetate, polymethyl methacrylate, cellulose derivatives such as ethyl cellulose, hydroxyl propyl methyl cellulose, sugar derivatives (gums) including derivatives of sorbitol and mannitol, silicone oil and silicone oil derivatives, polysiloxanes including amine-resistant polysiloxanes, and siloxanes.
8. The matrix layer of claim 6 , wherein the polymer carrier is selected from acrylates, povidones, siloxanes, polyvinyl pyrrolidone, polysiloxanes, amine-resistant polysiloxanes, polyalkyl acrylates, and polymethyl methacrylates.
9. The matrix layer of claim 1 , wherein the polymer carrier is present in an amount within the range of about 30% w/w to about 80% w/w, or within the range of about 55% w/w to about 65% w/w, of the total weight of the matrix layer.
10. The matrix layer of claim 1 , wherein the polymer carrier is present in an amount within the range of about 85% w/w to about 95% w/w, or within the range of about 90% w/w to about 95% w/w, of the total weight of the matrix layer.
11. The matrix layer of claim 1 , wherein the polymer carrier further comprises inert carrier components selected from the group consisting of anti-tacking agents, tackifiers, and plasticizers.
12. The matrix layer of claim 11 , wherein the anti-tacking agent is succinic acid.
13. The matrix layer of claim 11 , wherein the anti-tacking agent is present in an amount of less than about 1% w/w, up to about 1% w/w, or up to about 5% w/w, of the total weight of the matrix layer.
14. (canceled)
15. The matrix layer of claim 11 , wherein the tackifier is selected from the group consisting of acrylic, N-butyl-methacrylic copolymer, acrylic methyl, acrylic 2-ethylhexyl copolymer, polyacrylic acid, methacrylic copolymer L, aminoalkylmethacrylate copolymer E, rosin esters, hydrogenated rosins, dipropylene glycol dibenzoate, mixed hydrocarbons, and acrylic copolymers.
16. The matrix layer of claim 11 , wherein the plasticizer is selected from the group consisting of phthalates, esters of polycarboxylic acids with linear or branched aliphatic alcohols of moderate chain length, acetylated monoglycerides, alkyl citrates, triethyl citrate (TEC), acetyl triethyl citrate (ATEC), tributyl citrate (TBC), acetyl tributyl citrate (ATBC), trioctyl citrate (TOC), acetyl trioctyl citrate (ATOC), trihexyl citrate (THC), acetyl trihexyl citrate (ATHC), butyryl trihexyl citrate (BTHC, trihexyl o-butyryl citrate), trimethyl citrate (TMC), methyl laurate, lauric acid, lauryl lactate, lauryl alcohol, alkyl sulphonic acid phenyl ester, diethylene glycol monoethyl ether, bis(2-ethylhexyl) phthalate (DEHP), diisooctyl phthalate (DIOP), bis(n-butyl)phthalate (DnBP, DBP), diisobutyl phthalate (DIBP), bis(2-ethylhexyl)adipate (DEHA), dimethyl adipate (DMAD), monomethyl adipate (MMAD), dioctyl adipate (DOA), ethyl oleate, sorbitan monooleate, glycerol monooleate, dibutyl sebacate (DBS), dibutyl maleate (DBM), diisobutyl maleate (DIBM), benzoates, epoxidized vegetable oils, tris(tromethamine), N-ethyl toluene sulfonamide (o/p ETSA), N-(2-hydroxypropyl) benzene sulfonamide (HP BSA), N-(n-butyl) benzene sulfonamide (BBSA-NBBS), tricresyl phosphate (TCP), tributyl phosphate (TBP), triethylene glycol dihexanoate (3G6, 3GH), tetraethylene glycol diheptanoate (4G7), 1,3-butyleneglycol, dipropylene glycol, PEG400, Span 80, and polyvinylpyrrolidone.
17. The matrix layer of claim 11 , wherein the inert carrier components are present in an amount within the range of 0.001% w/w to about 50% w/w, within the range of 0.001% w/w to about 40% w/w, or within the range of 0.001% w/w to about 30% w/w, of the total weight of the matrix layer.
18. The matrix layer of claim 1 , wherein the matrix layer comprises an anti-tacking agent and a plasticizer in a total amount of about 35% w/w of the total weight of the matrix layer.
19. The matrix layer of claim 18 , wherein the anti-tacking agent is succinic acid and the plasticizer is dibutyl sebacate.
20. The matrix layer of claim 1 , wherein the polymer carrier and optional inert carrier components is present in an amount within the range of about 50% w/w to about 99% w/w, within the range of about 80% w/w to about 98% w/w, within the range of about 90% w/w to about 98% w/w, or in an amount of about 95% w/w, of the total weight of the matrix layer.
21.-22. (canceled)
23. A transdermal delivery patch for administration of a biologically active compound comprising a matrix layer as defined in claim 1 .
24.-40. (canceled)
41. A method for preparing a transdermal delivery patch for administration of a bioloigically active compound comprising the steps of:
(i) combining a polymer carrier and optional inert carrier components with a suitable solvent;
(ii) combining (i) with a dispersion comprising a biologically active compound and a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound;
(iii) stirring (ii) until complete homogenisation is achieved;
(iv) placing the composition of (iii) in a suitable mould or casting the composition of (iii) on a surface;
(v) drying the composition under heat.
42.-43. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/065,510 US20160184436A1 (en) | 2010-03-30 | 2016-03-09 | Transdermal delivery patch |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31900710P | 2010-03-30 | 2010-03-30 | |
US31900210P | 2010-03-30 | 2010-03-30 | |
PCT/AU2011/000358 WO2011120084A1 (en) | 2010-03-30 | 2011-03-30 | Transdermal delivery patch |
US201213501500A | 2012-04-12 | 2012-04-12 | |
US14/086,738 US20140155495A1 (en) | 2010-03-30 | 2013-11-21 | Transdermal delivery patch |
US14/550,514 US9314527B2 (en) | 2010-03-30 | 2014-11-21 | Transdermal delivery patch |
US15/065,510 US20160184436A1 (en) | 2010-03-30 | 2016-03-09 | Transdermal delivery patch |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/550,514 Continuation US9314527B2 (en) | 2010-03-30 | 2014-11-21 | Transdermal delivery patch |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160184436A1 true US20160184436A1 (en) | 2016-06-30 |
Family
ID=44711223
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/501,500 Active US8652511B2 (en) | 2010-03-30 | 2011-03-30 | Transdermal delivery patch |
US14/086,738 Abandoned US20140155495A1 (en) | 2010-03-30 | 2013-11-21 | Transdermal delivery patch |
US14/550,514 Active US9314527B2 (en) | 2010-03-30 | 2014-11-21 | Transdermal delivery patch |
US15/065,510 Abandoned US20160184436A1 (en) | 2010-03-30 | 2016-03-09 | Transdermal delivery patch |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/501,500 Active US8652511B2 (en) | 2010-03-30 | 2011-03-30 | Transdermal delivery patch |
US14/086,738 Abandoned US20140155495A1 (en) | 2010-03-30 | 2013-11-21 | Transdermal delivery patch |
US14/550,514 Active US9314527B2 (en) | 2010-03-30 | 2014-11-21 | Transdermal delivery patch |
Country Status (17)
Country | Link |
---|---|
US (4) | US8652511B2 (en) |
EP (1) | EP2552486B1 (en) |
JP (1) | JP5806287B2 (en) |
KR (1) | KR20130010473A (en) |
CN (1) | CN102821791B (en) |
AU (1) | AU2011235597B2 (en) |
BR (1) | BR112012024835A2 (en) |
CA (1) | CA2794734C (en) |
ES (1) | ES2829386T3 (en) |
IL (1) | IL222226A (en) |
MX (1) | MX2012011355A (en) |
NZ (1) | NZ602572A (en) |
RU (1) | RU2553350C2 (en) |
SG (1) | SG184181A1 (en) |
TW (1) | TWI507193B (en) |
WO (1) | WO2011120084A1 (en) |
ZA (1) | ZA201207074B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
US10188670B2 (en) | 2011-03-15 | 2019-01-29 | Phosphagenics Limited | Composition |
US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
WO2024030855A3 (en) * | 2022-08-01 | 2024-03-14 | Vitamax Patch Wholesaler Llc | Systems and methods for transdermal patch delivery |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102821791B (en) | 2010-03-30 | 2015-06-17 | 磷肌酸有限公司 | Transdermal delivery patch |
WO2012092986A1 (en) | 2011-01-07 | 2012-07-12 | Omya Development Ag | Process for water based mineral material slurry surface whitening |
LT2680832T (en) | 2011-03-04 | 2019-10-25 | Gruenenthal Gmbh | Aqueous pharmaceutical formulation of tapentadol for oral administration |
MX344473B (en) * | 2011-03-04 | 2016-12-16 | Gruenenthal Gmbh | Semisolid aqueous pharmaceutical composition containing tapentadol. |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
CA2790749A1 (en) * | 2011-09-29 | 2013-03-29 | Nitto Denko Corporation | Manufacturing method of patch preparation |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2885523T3 (en) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
JP6370802B2 (en) * | 2012-12-28 | 2018-08-08 | テイコク ファーマ ユーエスエー インコーポレーテッド | Long-acting buprenorphine transdermal delivery composition and methods of use thereof |
US9072682B2 (en) * | 2012-12-31 | 2015-07-07 | Mylan Inc. | Transdermal dosage form for low-melting point active agent |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
WO2016018993A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
KR101688061B1 (en) * | 2014-10-06 | 2017-01-02 | 주식회사한국파마 | Transdermal drug delivery system comprising pilocarpine |
JP2017531026A (en) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | Sustained release abuse deterrent liquid filler form |
US10028904B2 (en) | 2014-12-04 | 2018-07-24 | Wisconsin Alumni Research Foundation | Transdermal cannabinoid formulations |
US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
PT3479823T (en) | 2015-03-27 | 2020-09-29 | Gruenenthal Gmbh | Stable formulation for parenteral administration of tapentadol |
EP3299376A4 (en) * | 2015-05-20 | 2018-12-19 | Showa Denko K.K. | Tocopherol phosphate ester salt and method for producing same, and external skin preparation |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US11485699B2 (en) | 2016-07-06 | 2022-11-01 | Synthomer Adhesive Technologies Llc | (Meth)acrylic oligomers |
KR20190057349A (en) | 2016-09-23 | 2019-05-28 | 그뤼넨탈 게엠베하 | Stable formulation for parenteral administration of tapentadol |
KR102499141B1 (en) * | 2016-10-31 | 2023-02-13 | 신신제약 주식회사 | Percutaneous absorption system for the treatment of sleep disorders |
US20200060311A1 (en) * | 2016-12-09 | 2020-02-27 | Avecho Biotechnology Limited | A method for improving performance parameters of an animal |
AU2018205529B2 (en) | 2017-01-06 | 2023-08-10 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
BR112019014236A2 (en) | 2017-01-23 | 2020-03-17 | Afyx Therapeutics A/S | METHOD FOR MANUFACTURING A TWO-LAYER PRODUCT BASED ON ELECTROFIED FIBERS |
JP6977036B2 (en) * | 2017-06-30 | 2021-12-08 | 富士フイルム株式会社 | Pretreatment liquid for non-penetrating medium printing, printing substrate, manufacturing method of printing substrate, image recording method and ink set |
WO2019067670A1 (en) * | 2017-09-27 | 2019-04-04 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
EP3695829A4 (en) * | 2017-10-11 | 2021-07-14 | Showa Denko K.K. | Gel composition |
RU2017138097A (en) * | 2017-11-01 | 2019-05-07 | Анастасия Владимировна Серебрянская | TRANSDERMAL THERAPEUTIC PREPARATION |
BR112020010195A2 (en) * | 2017-12-20 | 2020-11-03 | Lts Lohmann Therapie-Systeme Ag | frigoestable composition for iontophoretic transdermal delivery of a triptan compound |
CN108434125B (en) * | 2018-04-25 | 2020-11-03 | 福州大学 | Preparation method of mesoporous silica-insulin nano sustained-release transdermal patch |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
DE102019120403A1 (en) * | 2019-07-29 | 2021-02-04 | Lts Lohmann Therapie-Systeme Ag | Process for the production of pressure-sensitive adhesives for use in a transdermal therapeutic system |
CN112057437B (en) * | 2019-12-10 | 2021-08-06 | 江苏一全药业有限公司 | Pharmaceutical preparation containing hyaluronic acid, pharmaceutical transdermal patch and preparation method thereof |
GB2608314A (en) * | 2020-02-11 | 2022-12-28 | Babak Ghalili | Cannabinoid and menthol transdermal delivery systems and methods |
US20230123388A1 (en) * | 2020-04-14 | 2023-04-20 | Glanis Pharmaceuticals, Inc. | Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine |
IL299453A (en) | 2020-06-17 | 2023-02-01 | Psilo Scient Ltd | Psychoactive alkaloid extraction and composition with inhibited dephosphorylation |
CA3197443A1 (en) | 2020-12-28 | 2022-06-28 | Psilo Scientific Ltd. | Processes for extracting psychoactive alkaloids and preparation thereof into transmucosal forms |
US11369789B2 (en) | 2021-04-05 | 2022-06-28 | Ishaan Jain | Transdermal drug delivery system |
CN114588133A (en) * | 2022-03-14 | 2022-06-07 | 南方医科大学深圳医院 | An oxycodone-containing topical analgesic patch for skin and its preparation method |
WO2024090634A1 (en) * | 2022-10-28 | 2024-05-02 | 주식회사 오가시스 | Skin whitening composition including κ-opioid receptor agonist |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054674A1 (en) * | 2000-01-26 | 2001-08-02 | F.T. Holdings S.A. | Patch for local and transdermal administration of active ingredients containing anionic or electron-attracting groups |
WO2006133506A1 (en) * | 2005-06-17 | 2006-12-21 | Vital Health Sciences Pty Ltd | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
US8652511B2 (en) * | 2010-03-30 | 2014-02-18 | Phosphagenics Limited | Transdermal delivery patch |
Family Cites Families (259)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2407823A (en) | 1946-09-17 | Antihemorrhagic esters and methods | ||
US2457932A (en) | 1949-01-04 | Salts of tocopheryl phosphoric | ||
US2667479A (en) | 1951-01-30 | 1954-01-26 | Merck & Co Inc | Benzimidazole phosphate |
GB778142A (en) | 1953-11-20 | 1957-07-03 | Leo Ab | High-molecular weight derivatives of hydroxyl group-containing steroids and a method of producing them |
US2913477A (en) | 1957-03-22 | 1959-11-17 | Merck & Co Inc | Antihemorrhagic compounds and processes for preparing the same |
US3127434A (en) | 1959-10-20 | 1964-03-31 | Hoffmann La Roche | Dihydrovitamin k monophosphate compounds and preparation thereof |
US3212901A (en) | 1961-06-07 | 1965-10-19 | Eastman Kodak Co | Stabilized tocopherol concentrates and process for preparing the same |
US3331896A (en) | 1964-09-15 | 1967-07-18 | Gen Aniline & Film Corp | Method of preparing alkali soluble phosphate esters of hydroxylic organic compounds |
US3607765A (en) | 1968-11-29 | 1971-09-21 | Colgate Polmolive Co | Detergent softener compositions |
JPS5239013Y2 (en) | 1971-10-11 | 1977-09-03 | ||
JPS5022535Y2 (en) | 1971-11-08 | 1975-07-08 | ||
JPS5315381Y1 (en) | 1974-06-06 | 1978-04-22 | ||
DE2526938C2 (en) | 1975-02-14 | 1982-04-22 | F. Hoffmann-La Roche & Co. AG, 4002 Basel | Vitamin preparations |
US4141938A (en) | 1976-10-07 | 1979-02-27 | Hoechst Aktiengesellschaft | Production of acid orthophosphoric acid ester mixtures |
US4444755A (en) | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
US4299906A (en) | 1979-06-01 | 1981-11-10 | American Hoechst Corporation | Light-sensitive color proofing film with surfactant in a light-sensitive coating |
SU925961A1 (en) | 1980-08-15 | 1982-05-07 | Московский ордена Трудового Красного Знамени технологический институт пищевой промышленности | Process for producing higher fatty acid phosphorilated glycerides |
JPS5944375B2 (en) | 1981-07-01 | 1984-10-29 | 日本鉱業株式会社 | Method for selectively removing calcium in solution |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
IT1157269B (en) | 1982-03-19 | 1987-02-11 | Seuref Ag | NEW PHARMACEUTICAL FORMULATIONS CONTAINING COENZYME Q10 SUITABLE FOR TOPICAL ADMINISTRATION |
JPS58180410U (en) | 1982-05-28 | 1983-12-02 | 東芝プラント建設株式会社 | plumb bob |
JPS59157091U (en) | 1983-04-04 | 1984-10-22 | 日本建鐵株式会社 | Packaging for fittings |
JPS60197621A (en) | 1984-03-19 | 1985-10-07 | Hohnen Oil Co Ltd | Hypocholesterolemic |
CH661438A5 (en) | 1984-04-09 | 1987-07-31 | Seuref Ag | Pharmaceutical compositions acting antianossica and metabolic brain. |
US4977282A (en) | 1984-04-17 | 1990-12-11 | Henkel Corporation | Production of d-alpha-tocopherol from natural plant sources |
US4603142A (en) | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
EP0171009B1 (en) | 1984-08-02 | 1991-05-22 | HENKEL CORPORATION (a Delaware corp.) | Purification of tocopherols by extraction |
JPS6191137A (en) | 1984-10-11 | 1986-05-09 | Kao Corp | External drug composition |
JPS6186940U (en) | 1984-11-12 | 1986-06-07 | ||
JPS6191137U (en) | 1984-11-19 | 1986-06-13 | ||
JP2540294B2 (en) | 1985-04-09 | 1996-10-02 | 花王株式会社 | Transdermal formulation |
JPS6220822Y2 (en) | 1985-04-17 | 1987-05-27 | ||
JPH05946Y2 (en) | 1985-07-30 | 1993-01-12 | ||
JPS62195393U (en) | 1986-05-29 | 1987-12-11 | ||
JPS6399150A (en) | 1986-10-14 | 1988-04-30 | Nippon Steel Corp | Two-side inverting device for member |
JPH0781138B2 (en) | 1986-12-02 | 1995-08-30 | 株式会社資生堂 | Antioxidant |
JPS6393791U (en) | 1986-12-08 | 1988-06-17 | ||
DE3702766A1 (en) | 1987-01-30 | 1988-08-11 | Henkel Kgaa | METHOD FOR PRODUCING AND ISOLATING MONOALKYLPHOSPHORIC ACID ESTERS |
JP3070744B2 (en) | 1987-04-10 | 2000-07-31 | 株式会社日立製作所 | Vector processing equipment |
US4952495A (en) | 1987-06-08 | 1990-08-28 | Eastman Kodak Company | Hydrolyzable compounds which release electron transfer agents and analytical use of same |
PH25859A (en) | 1988-01-11 | 1991-12-02 | Takeda Chemical Industries Ltd | Composition for treatment of ischemic disorder |
US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
DE3813624A1 (en) | 1988-04-22 | 1989-11-02 | Basf Ag | METHOD FOR PRODUCING D- (ALPHA) -TOCOPHEROL FROM NATURAL PRE-PRODUCTS |
CA2007643A1 (en) | 1989-02-01 | 1990-08-01 | Donald S. Karanewsky | Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination |
US6028105A (en) | 1989-04-06 | 2000-02-22 | Nigra; Thomas P. | Topical drug delivery composition and method |
US5053222A (en) | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
US5094848A (en) | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
DE3927113C2 (en) | 1989-08-17 | 1993-11-25 | Dolorgiet Gmbh & Co Kg | Agent for the treatment of severe pain conditions and process for their preparation |
JPH03120230A (en) | 1989-10-04 | 1991-05-22 | Nippon Mining Co Ltd | Percutaneous absorbefacient of drug active ingredient and percutaneous absorption type pharmaceutical |
JP2854631B2 (en) | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | Prevention and treatment of diabetic complications and diseases caused by aging |
IT1236843B (en) | 1989-11-22 | 1993-04-21 | Simes | PROCESS FOR THE PREPARATION OF 4-0-DOPAMINE PHOSPHATES OR ITS DERIVATIVES |
JPH03206089A (en) | 1990-01-05 | 1991-09-09 | Eisai Co Ltd | New vitamin e derivative and production thereof |
US5374645A (en) | 1990-01-22 | 1994-12-20 | Ciba-Geigy Corporation | Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol |
FR2657526B1 (en) | 1990-01-31 | 1994-10-28 | Lvmh Rech | USE OF AN ALPHA-TOCOPHEROL PHOSPHATE, OR ONE OF ITS DERIVATIVES, FOR THE PREPARATION OF COSMETIC, DERMATOLOGICAL, OR PHARMACEUTICAL COMPOSITIONS; COMPOSITIONS THUS OBTAINED. |
US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
US5114957A (en) | 1990-05-08 | 1992-05-19 | Biodor U.S. Holding | Tocopherol-based antiviral agents and method of using same |
CA2081982A1 (en) | 1990-05-21 | 1991-11-22 | Kenneth John Murray | Phenol and pyridinol derivatives as pharmaceuticals |
CA2067754C (en) | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
WO1992007544A1 (en) | 1990-10-26 | 1992-05-14 | Shiseido Co., Ltd. | External preparation for skin |
SE9003665D0 (en) | 1990-11-16 | 1990-11-16 | Kabivitrum Ab | MORPHINE PRODRUGS |
US5646190A (en) | 1991-03-01 | 1997-07-08 | Warner-Lambert Company | Acne treating-wound healing compositions and methods for preparing and using same |
FR2679904A1 (en) | 1991-08-01 | 1993-02-05 | Lvmh Rech | Use of a tocopherol phosphate, or of one of its derivatives, in the preparation of cosmetic or pharmaceutical compositions and compositions thus obtained |
US5643597A (en) | 1991-08-01 | 1997-07-01 | Lvmh Recherche | Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained |
EP0535283A1 (en) | 1991-10-02 | 1993-04-07 | Merrell Dow Pharmaceuticals Inc. | Cardioprotective tocopherol analogs |
US5474891A (en) | 1991-10-30 | 1995-12-12 | Thomas Jefferson University | Plasma-based platelet concentrate preparations with additive |
EP0612521B1 (en) | 1991-11-11 | 1999-06-30 | Hisamitsu Pharmaceutical Co., Inc. | Fomentation containing ketorolac |
EP0543417A1 (en) | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
US5282312A (en) | 1991-12-31 | 1994-02-01 | Tessera, Inc. | Multi-layer circuit construction methods with customization features |
AU3662093A (en) | 1992-02-14 | 1993-09-03 | Robert Lamb | Phosphate derivatives of vitamin e to protect cells from effects of aging and injury |
JP3207494B2 (en) | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | Aqueous suspension formulation |
JPH05286848A (en) | 1992-04-10 | 1993-11-02 | Senju Pharmaceut Co Ltd | Bathing agent |
US5731299A (en) | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
GB9212450D0 (en) | 1992-06-11 | 1992-07-22 | Indena Spa | New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them |
US5741518A (en) | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
US5773457A (en) | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
US5348357A (en) | 1992-12-24 | 1994-09-20 | General Motors Corporation | Vehicle closure latch having plastic coated ratchet |
US6384043B1 (en) | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
TW252918B (en) | 1993-03-31 | 1995-08-01 | Senju Pharma Co | |
DE4336557C2 (en) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiol-containing transdermal therapeutic system, process for its preparation and its use |
CN1077800C (en) | 1993-07-01 | 2002-01-16 | 韩美药品工业株式会社 | Cyclosporin soft capsule composition |
GB9318271D0 (en) | 1993-09-03 | 1993-10-20 | Scotia Holdings Plc | Tocopherols |
CA2129509A1 (en) | 1993-09-10 | 1995-03-11 | Kazumi Ogata | Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis |
WO1995014457A1 (en) | 1993-11-27 | 1995-06-01 | Knoll Ag | Compositions comprising iminium ion scavengers and/or nitrite scavengers |
JPH07196516A (en) | 1993-12-29 | 1995-08-01 | Senju Pharmaceut Co Ltd | Therapeutic agent for hemorrhoids |
FR2714595B1 (en) | 1993-12-30 | 1996-02-02 | Oreal | Water in oil emulsion containing retinol, its use and packaging. |
FR2715565B1 (en) | 1994-01-31 | 1996-03-15 | Oreal | Stabilized cosmetic or dermatological composition containing several precursors of the same active ingredient to maximize its release, its use. |
EP0669132A1 (en) | 1994-02-23 | 1995-08-30 | van der Kraaij, Antonius Marinus Maria | Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis |
CA2145229A1 (en) | 1994-03-29 | 1995-09-30 | Tetsuya Toge | Suppressory compositions against hepatic metastases of tumors |
US5554781A (en) | 1994-03-30 | 1996-09-10 | Reierson; Robert L. | Monoalkyl phosphonic acid ester production process |
JPH07277988A (en) | 1994-04-05 | 1995-10-24 | Senju Pharmaceut Co Ltd | Locally itch-removing and treating agent |
TW287103B (en) | 1994-04-22 | 1996-10-01 | Senju Pharma Co | |
JP3362501B2 (en) | 1994-04-28 | 2003-01-07 | 千寿製薬株式会社 | Corneal disorder treatment |
JP3396953B2 (en) | 1994-05-10 | 2003-04-14 | 千寿製薬株式会社 | Retinal disease prevention / treatment agent |
GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
AU2825295A (en) | 1994-06-13 | 1996-01-05 | Arcturus Pharmaceutical Corporation | Method for the treatment, prevention or minimization of hair loss |
US5589504A (en) | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
CA2152693A1 (en) | 1994-08-05 | 1996-02-06 | Kazumi Ogata | Therapeutic composition for pancreatitis |
IT1274734B (en) | 1994-08-25 | 1997-07-24 | Prospa Bv | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS |
HU215966B (en) | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Oral multiple emulsion-preconcentrate containing cyclosporin |
KR100261858B1 (en) | 1994-12-09 | 2000-07-15 | 고토다쿠야 | Process for the preparation of phosphoric monoester |
DE4444238A1 (en) | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
SE9404568L (en) | 1994-12-30 | 1996-07-01 | Perstorp Ab | Use of inositol trisphosphate for drug preparation |
AU4515996A (en) | 1995-01-09 | 1996-07-31 | Alpha-Therapeutics, Inc. | Methods for increasing the bioavailability of biological active agents |
FR2730928B1 (en) | 1995-02-23 | 1997-04-04 | Oreal | COMPOSITION BASED ON LIPIDIC VESICLES WITH ACIDIC PH AND USE THEREOF IN TOPICAL APPLICATION |
JPH08231564A (en) | 1995-02-28 | 1996-09-10 | Nippon Shokubai Co Ltd | Phosphoric acid ester, its production and phosphoric acid ester polymer |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
EP0766960B1 (en) | 1995-04-21 | 2003-09-17 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
US5665389A (en) | 1995-05-24 | 1997-09-09 | University Of Maryland At Baltimore | Oral dosage composition for intestinal delivery and method of treating diabetes |
US5607968A (en) | 1995-06-07 | 1997-03-04 | Avon Products, Inc. | Topical alkyl-2-O-L-ascorbyl-phosphates |
JP3609834B2 (en) | 1995-07-12 | 2005-01-12 | 株式会社 資生堂 | Skin preparation |
JP4115524B2 (en) | 1995-10-17 | 2008-07-09 | 昭和電工株式会社 | High-purity tocopherol phosphates, production method thereof, analysis method thereof and cosmetics |
FR2741263B1 (en) | 1995-11-22 | 1997-12-26 | Oreal | COMPOSITION COMPRISING AN AQUEOUS DISPERSION OF LIPID VESICLES ENCAPSULATING AN ACID-FUNCTIONAL UV FILTER AND USES FOR TOPICAL APPLICATION |
CN1229114C (en) | 1996-03-27 | 2005-11-30 | 印斯拜尔药品股份有限公司 | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds |
US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US5885595A (en) | 1996-05-13 | 1999-03-23 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic composition with a retinol fatty acid ester |
JPH1045783A (en) | 1996-07-29 | 1998-02-17 | Showa Denko Kk | Production of hydroxychromanic acid derivative phosphoric ester |
CA2209690A1 (en) | 1996-07-31 | 1998-01-31 | Sachiko Matsuura | Therapeutic drug for acne vulgaris |
JPH1067639A (en) | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | Vitamin e-vitamin c phosphoric diester/cyclodextrin clathrate and external preparation for skin containing the same |
US6022867A (en) | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
JPH10155429A (en) | 1996-11-27 | 1998-06-16 | Showa Denko Kk | Method for supplying vitamin e to animals and tocopherol phosphate for animals or its salts composition |
US6727280B2 (en) | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6932975B2 (en) | 1997-01-29 | 2005-08-23 | Kao Corporation | Cosmetic composition comprising a phosphoric triester and a skin activating component |
US5804168A (en) | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
US6248758B1 (en) | 1997-03-13 | 2001-06-19 | Hexal Ag | Pharmaceutical antacid |
US7179486B1 (en) | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
FR2764891B1 (en) | 1997-06-04 | 2001-04-13 | Pacific Corp | DERIVED FROM L-ASCORBIC ACID STABLE IN WATER, PROCESS FOR ITS PREPARATION AND COSMETIC COMPOSITION OF BLEACHING THE SKIN CONTAINING IT |
US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
JPH1143436A (en) | 1997-07-25 | 1999-02-16 | Showa Denko Kk | Medicine for preventing/treating periphery blood stream disorder |
US5776915A (en) | 1997-08-12 | 1998-07-07 | Clarion Pharmaceuticals Inc. | Phosphocholines of retinoids |
US6096326A (en) | 1997-08-15 | 2000-08-01 | Scandinavian-American Import/Export Corporation | Skin care compositions and use |
IT1294748B1 (en) | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | FORMULATION FOR A TRANSDERMAL DEVICE |
JP3950216B2 (en) | 1997-12-26 | 2007-07-25 | 日本メナード化粧品株式会社 | Topical skin preparation |
WO1999033846A2 (en) | 1997-12-31 | 1999-07-08 | The University Of Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
JPH11199465A (en) | 1998-01-07 | 1999-07-27 | Nonogawa Shoji Kk | Skin preparation for external use |
AU2113199A (en) | 1998-01-12 | 1999-07-26 | Betagene, Inc. | Media for neuroendocrine cells |
EP1053749A4 (en) | 1998-02-03 | 2003-01-15 | Senju Pharma Co | Preventives and remedies for neuron digeneration-associated diseaseas |
FR2777179A1 (en) | 1998-04-09 | 1999-10-15 | Lvmh Rech | Cosmetic and dermatological composition with non-greasy feel and useful as carrier |
US6461623B2 (en) | 1998-04-13 | 2002-10-08 | Kao Corporation | Cosmetic composition |
US6254853B1 (en) | 1998-05-08 | 2001-07-03 | Vyrex Corporation | Water soluble pro-drugs of propofol |
JP4208209B2 (en) | 1998-06-22 | 2009-01-14 | フジノン株式会社 | Collimator lens and optical scanning device using the same |
US6121249A (en) | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
ATE399565T1 (en) | 1998-07-07 | 2008-07-15 | Transdermal Technologies Inc | COMPOSITIONS FOR THE RAPID AND NON-IRRITATIVE TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHODS OF FORMULATION AND ADMINISTRATION THEREOF |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
US6770672B1 (en) | 1998-09-23 | 2004-08-03 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6703384B2 (en) | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
IL142082A (en) | 1998-09-23 | 2005-12-18 | Res Dev | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
IT1303787B1 (en) | 1998-11-25 | 2001-02-23 | Maria Rosa Gasco | "SOLID LIPID NANOSPHERES SUITABLE FOR FAST INTERNALIZATION IN THE CELLS" |
US6048891A (en) | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
AUPP829399A0 (en) | 1999-01-25 | 1999-02-18 | Swig Pty Ltd | Recovery for chroman derivatives |
AUPQ037499A0 (en) | 1999-05-14 | 1999-06-10 | Swig Pty Ltd | Improved process for phosphorylation and compounds produced by this method |
JP2000212082A (en) | 1999-01-26 | 2000-08-02 | Showa Denko Kk | Preparation for external use for skin |
NZ527924A (en) | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
US6156354A (en) | 1999-01-29 | 2000-12-05 | Brandeis University | Hyper-absorption of vitamin E dispersed in milks |
DE19912798C1 (en) | 1999-03-10 | 2000-02-17 | Andreas Jordan | Culturing human cancer cells for molecular biology research comprises culturing fragments of tissue slices |
AU3913800A (en) | 1999-03-26 | 2000-10-16 | Lipogenics, Inc. | Novel antioxidant formulations and methods for using them |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
CA2372066C (en) | 1999-05-14 | 2006-01-31 | Simon Michael West | Process for phosphorylation of primary fatty alcohols,secondary alcohols and aromatic alcohols using p4o10 in the absence of solvent |
DE19922662C1 (en) * | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermal therapeutic system (TTS) containing tolterodine |
DE19923551A1 (en) | 1999-05-21 | 2000-11-30 | Lohmann Therapie Syst Lts | Pharmaceutical preparation with the active ingredient diamorphine and its use in a method for treating opiate addiction |
US6184247B1 (en) | 1999-05-21 | 2001-02-06 | Amway Corporation | Method of increasing cell renewal rate |
AU5594700A (en) | 1999-06-01 | 2000-12-18 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
EP1187618A1 (en) | 1999-06-04 | 2002-03-20 | The General Hospital Corporation | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
NZ517833A (en) | 1999-08-20 | 2004-01-30 | Ferrosan As | Oral delivery of antioxidants vitamin C and vitamin E combinations in slow- and plain-release formulations for treating oxidative stress |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6423742B1 (en) | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
GB9921960D0 (en) | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and amino acids |
KR20020059415A (en) | 1999-09-27 | 2002-07-12 | 스티븐 씨. 큐웨이 | Compositions of tocol-soluble therapeutics |
WO2001035998A1 (en) | 1999-11-12 | 2001-05-25 | Pharmaderm Laboratories, Ltd. | Compositions for transdermal and transmucosal administration of therapeutic agents |
AU1780101A (en) * | 1999-11-19 | 2001-05-30 | Xel Herbaceuticals | Transdermal delivery system for alkaloids of aconitum species |
JP2001169731A (en) | 1999-12-17 | 2001-06-26 | Showa Denko Kk | Lipid metabolism improving agent for animal |
WO2001046204A1 (en) | 1999-12-22 | 2001-06-28 | Merck Frosst Canada & Co. | Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
KR100847678B1 (en) | 2000-02-11 | 2008-07-23 | 리서치 디벨럽먼트 파운데이션 | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6635253B2 (en) | 2000-02-29 | 2003-10-21 | Showa Denko Kabushiki Kaisha | Composition for enhancing immunological effects |
US6346544B2 (en) | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
JP2001247585A (en) | 2000-03-03 | 2001-09-11 | Nof Corp | Tocopherol derivative, intermediate for the same, method of producing the same, and application for the same |
US6444220B2 (en) | 2000-03-16 | 2002-09-03 | Teresa S. Wiley | Method and compositions for changing the contour of skin |
AU2001247726A1 (en) | 2000-03-24 | 2001-10-08 | Baker Norton Pharmaceuticals, Inc. | Taxane-based compositions and methods of use |
US6361800B1 (en) | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
FR2811546B1 (en) | 2000-07-13 | 2003-09-26 | Oreal | LONG-LASTING MAKEUP KIT AND METHOD |
US6485950B1 (en) | 2000-07-14 | 2002-11-26 | Council Of Scientific And Industrial Research | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions |
US6362234B1 (en) | 2000-08-15 | 2002-03-26 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migrane |
KR100365070B1 (en) | 2000-08-29 | 2002-12-16 | 주식회사 태평양 | Tocopherol derivatives and method for preparation thereof |
JP4818500B2 (en) | 2000-09-05 | 2011-11-16 | 株式会社ペンタプラストア | Tocotrienol derivative and method for producing the same |
WO2002026238A1 (en) | 2000-09-26 | 2002-04-04 | Vital Health Sciences Pty Ltd. | Phosphate derivative supplements |
US20030206972A1 (en) | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
AU2002220021A1 (en) | 2000-11-02 | 2002-05-15 | The Regents Of The University Of California | Alpha-tocopherol transfer protein knockout animals |
CN1262274C (en) | 2000-11-14 | 2006-07-05 | 生命健康科学有限公司 | Complexes of phosphate derivatives |
AU2002214820B2 (en) | 2000-11-14 | 2003-08-14 | Vital Health Sciences Pty Ltd | Formulation containing phosphate derivatives of electron transfer agents |
AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
AU2002228648A1 (en) | 2000-11-16 | 2002-05-27 | Pharmacia And Upjohn Company | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
WO2002047680A2 (en) | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
US20020151467A1 (en) | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
US20020131994A1 (en) | 2001-01-10 | 2002-09-19 | Schur Henry B. | Non-irritating formulation for the transdermal delivery of substances |
US6849271B2 (en) | 2001-04-27 | 2005-02-01 | Verion, Inc. | Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods |
TW576859B (en) | 2001-05-11 | 2004-02-21 | Shipley Co Llc | Antireflective coating compositions |
KR100394770B1 (en) | 2001-06-05 | 2003-08-14 | 주식회사 태평양 | Stabilization method of nano-emulsion using tocopheryl derivatives and external application for skin containing the stabilized nano-emulsion |
BR0211673A (en) | 2001-07-27 | 2004-07-13 | Vital Health Sciences Pty Ltd | Dermal therapy using phosphate derivatives of electron transfer agents |
AUPR684801A0 (en) | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
RU2302857C2 (en) * | 2001-09-04 | 2007-07-20 | Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель | Method and plaster for preventing and/or treating the cases of finger-nail dysfunction and/or growth disorders |
WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
AU2002951045A0 (en) | 2002-08-27 | 2002-09-12 | Vital Health Sciences Pty Ltd | Method of supplementing nascent endogenous storage forms |
WO2003026673A1 (en) | 2001-09-26 | 2003-04-03 | Vital Health Sciences Pty Ltd. | Modulation of vitamin storage |
JP4370451B2 (en) | 2001-09-28 | 2009-11-25 | 大塚製薬株式会社 | Pharmaceutical composition |
JP2003128531A (en) | 2001-10-17 | 2003-05-08 | Nonogawa Shoji Kk | Dermal external agent |
US20030144219A1 (en) | 2001-11-15 | 2003-07-31 | Phinney Stephen Dodge | Formulations and methods for treatment or amelioration of inflammatory conditions |
WO2003049774A1 (en) | 2001-12-13 | 2003-06-19 | Vital Health Sciences Pty Ltd | Transdermal transport of compounds |
IL162614A0 (en) | 2001-12-19 | 2005-11-20 | Res Dev Foundation | Liposomal delivery of vitamin e based compounds |
WO2003063860A1 (en) | 2002-01-31 | 2003-08-07 | Kansai Technology Licensing Organization Co., Ltd. | Compositions for preventing human cancer and method of preventing human cancer |
WO2003068209A1 (en) | 2002-02-14 | 2003-08-21 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
US7074825B2 (en) | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
CN1652746A (en) | 2002-05-09 | 2005-08-10 | 昭和电工株式会社 | Skin whitening external preparation |
EP1507813A4 (en) | 2002-05-20 | 2005-11-23 | Ranbaxy Lab Ltd | Fat binding using inter-polymer complex of glucosamine and polyacrylic acid |
US20040018237A1 (en) | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US20040067890A1 (en) | 2002-10-04 | 2004-04-08 | Gupta Shyam K. | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions |
FR2846651B1 (en) | 2002-10-30 | 2006-06-16 | Rhodia Polyamide Intermediates | PROCESS FOR PRODUCING CARBOXYLIC ACIDS |
US7399784B2 (en) | 2002-11-26 | 2008-07-15 | Children's Hospital & Research Center At Oakland | Tocopherol and tocotrienol anti-obesity medicaments |
US6645514B1 (en) | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
EP1578325B1 (en) | 2002-12-31 | 2011-04-27 | Transdermal Biotechnology, Inc. | Stable topical drug delivery compositions |
KR20050086954A (en) | 2003-01-17 | 2005-08-30 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | Compounds having anti-proliferative properties |
US7033998B2 (en) | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
AU2003901813A0 (en) | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Pharmaceutical derivatives |
AU2003901812A0 (en) | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
AU2003901815A0 (en) | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
JP2006199589A (en) | 2003-09-03 | 2006-08-03 | Ltt Bio-Pharma Co Ltd | Nanoparticle containing physiologically active protein or peptide, method for producing the same and external preparation comprising the nanoparticle |
CN100536845C (en) * | 2003-09-23 | 2009-09-09 | 中国医学科学院药物研究所 | Loratadine paster of penetrating skin |
US7207669B2 (en) | 2003-12-19 | 2007-04-24 | Arizona Chemical Company | Jet printing inks containing polymerized fatty acid-based polyamides |
PT2351555T (en) | 2004-02-23 | 2016-11-29 | Euro Celtique Sa | Abuse resistance opioid transdermal delivery device |
WO2005084678A1 (en) | 2004-03-03 | 2005-09-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
DE602005020638D1 (en) | 2004-06-29 | 2010-05-27 | Japan Science & Tech Agency | SELECTIVE CULTURING METHOD AND SEPARATION METHOD FOR SMALL HEPATOCYTES USING HYALURONIC ACID |
KR101238703B1 (en) | 2004-08-03 | 2013-03-04 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | Carrier for enteral administration |
US20060120979A1 (en) | 2004-12-02 | 2006-06-08 | Joel Rubin | Skin care composition comprising hydroquinone and a substantially anhydrous base |
US20090239827A1 (en) | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
CA2599424A1 (en) | 2005-03-03 | 2006-09-08 | Vital Health Sciences Pty Ltd | Compounds having anti-cancer properties |
CN101132789A (en) | 2005-03-03 | 2008-02-27 | 生命健康科学有限公司 | Compounds having lipid lowering properties |
JP4270212B2 (en) | 2005-03-29 | 2009-05-27 | セイコーエプソン株式会社 | Substrate spacing adjusting device, substrate spacing adjusting method, and liquid crystal display manufacturing method |
US20060228395A1 (en) | 2005-04-11 | 2006-10-12 | Robert Lamb | Vitamin E phosphate/phosphatidylcholine liposomes to protect from or ameliorate cell damage |
CN101247834B (en) * | 2005-06-17 | 2013-10-30 | 生命健康科学公司 | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
KR100764679B1 (en) | 2005-07-22 | 2007-10-09 | 익수제약 주식회사 | Patches comprising paroxetine for transdermal application |
US7446096B2 (en) * | 2005-12-19 | 2008-11-04 | Industrial Technology Research Institute | Glutathione based delivery system |
TW200800223A (en) | 2005-12-21 | 2008-01-01 | Shire Pharmaceuticals Inc | Transdermal delivery of meptazinol |
CA2631653A1 (en) | 2005-12-23 | 2007-06-28 | Vital Health Sciences Pty Ltd. | Compounds having cytokine modulating properties |
WO2008034178A1 (en) | 2006-09-21 | 2008-03-27 | Salvatore Iemma | Topical depilating composition |
RU2373957C2 (en) | 2006-10-13 | 2009-11-27 | Александр Метталинович Тишин | Therapeutic and diagnostic drug and biologically active substance carrier and application thereof for making drugs and method of regulated controlled drug or biologically active substance delivery with regulated desorption |
JP5201858B2 (en) | 2007-03-26 | 2013-06-05 | 花王株式会社 | Method for producing fats and oils with reduced free fatty acids |
FR2921259B1 (en) | 2007-09-26 | 2015-02-13 | Lvmh Rech | COSMETIC USE OF TOCOPHEROL PHOSPHATE AS AN ANTI-AGING SKIN AGENT |
EP2113242A1 (en) | 2008-05-02 | 2009-11-04 | Pangaea Laboratories Limited | Antioxidant for use in cosmetic, medicated and pharmaceutical preparations |
US20090297591A1 (en) | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
US20120202780A1 (en) | 2009-12-23 | 2012-08-09 | Paul David Gavin | Carrier composition |
RU2012133467A (en) | 2010-02-05 | 2014-02-10 | Фосфейдженикс Лимитед | CARRIER COMPOSITION |
AU2011213557B2 (en) | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
JP5132700B2 (en) | 2010-02-22 | 2013-01-30 | 三菱電機株式会社 | Hand dryer |
EP2685992A4 (en) | 2011-03-15 | 2014-09-10 | Phosphagenics Ltd | Amino-quinolines as kinase inhibitors |
-
2011
- 2011-03-30 CN CN201180017569.3A patent/CN102821791B/en active Active
- 2011-03-30 SG SG2012069993A patent/SG184181A1/en unknown
- 2011-03-30 WO PCT/AU2011/000358 patent/WO2011120084A1/en active Application Filing
- 2011-03-30 NZ NZ602572A patent/NZ602572A/en unknown
- 2011-03-30 BR BR112012024835A patent/BR112012024835A2/en not_active IP Right Cessation
- 2011-03-30 US US13/501,500 patent/US8652511B2/en active Active
- 2011-03-30 EP EP11761826.4A patent/EP2552486B1/en active Active
- 2011-03-30 RU RU2012141586/15A patent/RU2553350C2/en active
- 2011-03-30 AU AU2011235597A patent/AU2011235597B2/en active Active
- 2011-03-30 ES ES11761826T patent/ES2829386T3/en active Active
- 2011-03-30 CA CA2794734A patent/CA2794734C/en active Active
- 2011-03-30 TW TW100111019A patent/TWI507193B/en not_active IP Right Cessation
- 2011-03-30 KR KR1020127025679A patent/KR20130010473A/en not_active Application Discontinuation
- 2011-03-30 MX MX2012011355A patent/MX2012011355A/en active IP Right Grant
- 2011-03-30 JP JP2013501560A patent/JP5806287B2/en active Active
-
2012
- 2012-09-20 ZA ZA2012/07074A patent/ZA201207074B/en unknown
- 2012-09-27 IL IL222226A patent/IL222226A/en active IP Right Grant
-
2013
- 2013-11-21 US US14/086,738 patent/US20140155495A1/en not_active Abandoned
-
2014
- 2014-11-21 US US14/550,514 patent/US9314527B2/en active Active
-
2016
- 2016-03-09 US US15/065,510 patent/US20160184436A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001054674A1 (en) * | 2000-01-26 | 2001-08-02 | F.T. Holdings S.A. | Patch for local and transdermal administration of active ingredients containing anionic or electron-attracting groups |
WO2006133506A1 (en) * | 2005-06-17 | 2006-12-21 | Vital Health Sciences Pty Ltd | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
US20090036354A1 (en) * | 2005-06-17 | 2009-02-05 | Paul Gavin | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
US8652511B2 (en) * | 2010-03-30 | 2014-02-18 | Phosphagenics Limited | Transdermal delivery patch |
US9314527B2 (en) * | 2010-03-30 | 2016-04-19 | Phosphagenics Limited | Transdermal delivery patch |
Non-Patent Citations (1)
Title |
---|
Gianello et al., (Subchronic Oral Toxicity Study of Mixed Tocopheryl Phosphates in Rats, International Journal of Toxicology, 26:475-490; 2007). * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
US10188670B2 (en) | 2011-03-15 | 2019-01-29 | Phosphagenics Limited | Composition |
US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
WO2024030855A3 (en) * | 2022-08-01 | 2024-03-14 | Vitamax Patch Wholesaler Llc | Systems and methods for transdermal patch delivery |
Also Published As
Publication number | Publication date |
---|---|
AU2011235597B2 (en) | 2015-07-16 |
TW201201796A (en) | 2012-01-16 |
EP2552486A1 (en) | 2013-02-06 |
CN102821791A (en) | 2012-12-12 |
KR20130010473A (en) | 2013-01-28 |
RU2012141586A (en) | 2014-04-10 |
JP5806287B2 (en) | 2015-11-10 |
NZ602572A (en) | 2014-11-28 |
ES2829386T3 (en) | 2021-05-31 |
US20120201891A1 (en) | 2012-08-09 |
AU2011235597A1 (en) | 2012-10-18 |
US8652511B2 (en) | 2014-02-18 |
CA2794734C (en) | 2017-12-12 |
RU2553350C2 (en) | 2015-06-10 |
US20150148431A1 (en) | 2015-05-28 |
US9314527B2 (en) | 2016-04-19 |
EP2552486A4 (en) | 2014-07-09 |
IL222226A0 (en) | 2012-12-31 |
EP2552486B1 (en) | 2020-08-12 |
BR112012024835A2 (en) | 2016-06-07 |
MX2012011355A (en) | 2012-11-30 |
CA2794734A1 (en) | 2011-10-06 |
TWI507193B (en) | 2015-11-11 |
SG184181A1 (en) | 2012-10-30 |
WO2011120084A1 (en) | 2011-10-06 |
ZA201207074B (en) | 2013-05-29 |
IL222226A (en) | 2017-04-30 |
CN102821791B (en) | 2015-06-17 |
JP2013523660A (en) | 2013-06-17 |
US20140155495A1 (en) | 2014-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9314527B2 (en) | Transdermal delivery patch | |
US20190298834A1 (en) | Carrier composition | |
CZ291656B6 (en) | Transdermal therapeutic system in the form of a plaster containing estradiol and process for preparing thereof | |
AU2010336018B2 (en) | Carrier composition | |
US20130101660A1 (en) | Transdermal delivery patch | |
TW201141522A (en) | Carrier composition | |
US20110244023A1 (en) | Transdermal delivery patch | |
EP2886578A1 (en) | Hydrophilic skin adhesive | |
EP2853573A1 (en) | Skin friendly adhesive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PHOSPHAGENICS LIMITED, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COTTRELL, JEREMY;GAETANO, GIACINTO;EL-TAMIMY, MAHMOUD;AND OTHERS;SIGNING DATES FROM 20120408 TO 20120411;REEL/FRAME:037937/0495 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |